Advanced Search

Law on the marketing of narcotic drugs

Original Language Title: Gesetz über den Verkehr mit Betäubungsmitteln

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.

Law on the marketing of narcotic drugs (Narcotics Act-BtMG)

Unofficial table of contents

BtMG

Date of completion: 28.07.1981

Full quote:

" Narcotics Act as amended by the Notice of 1 March 1994 (BGBl. 358), most recently by Article 2 of the Law of 20 May 2015 (BGBl. I p. 725).

Status: New by Bek. v. 1.3.1994 I 358;
Last amended by Art. 2 G v. 20.5.2015 I 725

For more details, please refer to the menu under Notes

Footnote

(+ + + Text proof applicable: 1.8.1981 + + +) 
(+ + + Do not apply measures due to EinigVtr in accordance with the provisions of this Regulation). Art. 109 No. 4
Buchst. c DBuchst. aa G v. 8.12.2010 I 1864 mWv 15.12.2010 + + +)
(+ + + Official note from the norm-provider on EC law:
Consideration of
ERL 34/98 (CELEX Nr: 398L0034)
Notification of the
ERL 34/98 (CELEX Nr: 31998L0034 cf. V v. 18.5.2015 I 723 + + +)

The law was adopted as Article 1 of the G v. 28.7.1981 I 681 of the Bundestag with the consent of the Bundesrat. It is on 1.1.1982 in accordance with. Art. 7 (1) (d). Gzur Neuordnung d. Anaesthesiological law v. 28.7.1981 BGBl. 681, 1187 entered into force.
The provisions authorizing the adoption of legal regulations shall appear in accordance with the provisions of this Regulation. Art. 7 (1) (d). G to reorder d. Anaesthesiological law v. 28.7.1981 BGBl. 681, 1187 in force on the day after the announcement. The G was announced on 31 July 1981. Unofficial table of contents

Content Summary

First section
Definitions
§ 1 Anesthesials
§ 2 Other terms
Second section
Permission and permission procedure
§ 3 Permission to use narcotic drugs
§ 4 Derogations from the requirement to grant authorisation
§ 5 Failure of permission
§ 6 Expertise
§ 7 Application
§ 8 Decision
§ 9 Restrictions, restrictions, conditions and conditions
§ 10 Withdrawal and revocation
§ 10a Permission for the operation of drug consumption rooms
Third Section
Obligations in the field of narcotic drugs
§ 11 Import, export and transit
§ 12 Levy and acquisition
§ 13 Prescribtion and dispensing on prescription
§ 14 Labelling and advertising
§ 15 Security measures
§ 16 Destruction
§ 17 Records
§ 18 Notifications
Section 18a Prohibitions
Fourth Section
Monitoring
§ 19 Competent authority
§ 20 Special authorization for the case of a voltage or defence case
Section 21 Participation of other authorities
Section 22 Surveillance measures
Section 23 Sampling
§ 24 Obligation to take part in and to participate
§ 24a Display of the cultivation of usable hemp
Section 25 Fees and expenses
Fifth Section
Rules applicable to authorities
Section 26 Bundeswehr, federal police, riot police and civil protection
§ 27 Reports and information
§ 28 Annual report to the United Nations
Sixth Section
Offences and regularties
§ 29 Offences
§ 29a Offences
§ 30 Offences
§ 30a Offences
§ 30b Offences
§ 30c Financial penalty
Section 31 Penal alleviation or decrimination of punishment
Section 31a Watch from the persecution
Section 32 Irregularities
§ 33 Extended decay and confiscation
Section 34 Supervision
Seventh Section
Offenders-dependent offenders
§ 35 Reposition of the execution of the sentence
§ 36 Offsetting and punitisation of probation
Section 37 Watch from the persecution
§ 38 Young people and adolescents
Eighth section
Transitional and final provisions
§ 39 Transitional arrangements
Section 39a Transitional arrangements on the occasion of the law on the amendment of medicinal products and other provisions
§ 40 and § 40a (unopposed)
Section 41 (dropped)

First section
Definitions

Unofficial table of contents

§ 1 Narcotics

(1) Narcotic agents within the meaning of this Act are the substances and preparations listed in Annexes I to III. (2) The Federal Government is authorized, after consultation of experts, by means of a regulation with the consent of the Federal Council. Annexes I to III to be amended or supplemented where:
1.
in the light of scientific knowledge of the mode of action of a substance, in particular with regard to the emergence of dependence,
2.
due to the possibility of being able to produce narcotic drugs from a substance or using a substance, or
3.
on the safety or control of the transport of narcotic drugs or other substances or preparations because of the extent of misuse and because of the direct or indirect danger to health
is required. In the legal regulation referred to in the first sentence, individual substances or preparations may be exempted in whole or in part from the application of this law or by a regulation adopted pursuant to this Act, in so far as the security and the (3) The Federal Ministry of Health is authorized in urgent cases to ensure safety or control of the movement of narcotic drugs by means of a legal regulation without the consent of the Federal Council substances and preparations which are not medicinal products in Annexes I to III if this is necessary because of the extent of the abuse and because of the direct or indirect risk to health. The Federal Ministry of Health (Federal Ministry of Health) is authorized to act on the basis of this regulation without the consent of the Federal Council. until III or the legal regulations adopted pursuant to this Act, in so far as this is due to amendments to the Annexes to the Single Convention on Narcotic Drugs of 1961 as amended by the Notice of 4 February 1977 (BGBl. 111) and the Convention on Psychotropic Substances of 1971 (BGBl. 1477) (International Convention on Narcotic Drugs) is required in its version binding for the Federal Republic of Germany in each case. Unofficial table of contents

§ 2 Other terms

(1) For the purposes of this Act,
1.
Substance:
a)
chemical elements and chemical compounds as well as their naturally occurring mixtures and solutions,
b)
plants, algae, fungi and lichens as well as their parts and constituents in processed or unprocessed condition,
c)
Animal bodies, including live animals, as well as body parts, constituents and metabolic products of humans and animals in a processed or unprocessed condition,
d)
micro-organisms including viruses and their constituents or metabolic products;
2.
preparation: without regard to its state of aggregation, a mixture of substances or the solution of one or more substances other than the naturally occurring mixtures and solutions;
3.
the preparation of the composition: a preparation referred to in Annexes I to III, which is wholly or partly excluded from the provisions of the legislation on the treatment of stunning products;
4.
Manufacture: the winning, ready-to-use, ready-to-use, processing, cleaning and conversion.
(2) The import or export of a narcotic agent shall be equal to any other transfer in or out of the scope of this Act.

Second section
Permission and permission procedure

Unofficial table of contents

§ 3 Permission to traffic with narcotics

(1) A permission from the Federal Institute for Drugs and Medical Devices is required.
1.
Cultivate, manufacture, trade with them, import, export, supply, sell, sell or otherwise place on the market, without being able to trade with them, or
2.
prepared preparations (Section 2 (1) (3))
(2) The Federal Institute for Medicinal Products and Medical Devices may, exceptionally, grant a permit for the narcotics referred to in Annex I to scientific or other purposes in the public interest. Unofficial table of contents

§ 4 Exceptions to the authorisation requirement

(1) A permission in accordance with § 3 shall not be required:
1.
in the context of the establishment of a public pharmacy or a hospital pharmacy (pharmacy)
a)
produces or preparations of anesthetic or preparations referred to in Annex II or III,
b)
The use of narcotic drugs referred to in Annex II or III shall be
c)
In Annex III, narcotics referred to in Annex III shall be issued on the basis of medical, dental or veterinary prescriptions,
d)
Means of narcotics referred to in Annex II or III shall be returned to the holder of a permit for the acquisition of such narcotics or shall be sent to the successor in the operation of the pharmacy,
e)
Narcotics referred to in Annex I, II or III to investigate, transfer to a site entitled to investigate narcotic drugs, or to destroy them, or
f)
In Annex III, opioids in the form of ready-to-use medicinal products in transdermal or transmucosal dosage form to a pharmacy to cover the non-suspectable anesthetic needs of an outpatient palliative patient, if the receiving pharmacy does not have the narcotics in stock,
2.
Narcotics in the form of ready-to-use medicinal products, referred to in Annex III, to the establishment of a veterinary medicinal product
a)
in the case of an animal treated by him, mixing with one another, with other medicinal products for manufacture or with non-active medicinal products for the purpose of application by him or for immobilisation of a zoo, game and animal animal treated by him,
b)
,
c)
for an animal or a mixture referred to in (a) treated by him, for the immobilisation of a zoo, game and animal animal treated by him, or
d)
returns to the holder of the licence for the purchase of these narcotics or to the successor in the establishment of the veterinarian's home mortgage,
3.
Narcotic agents referred to in Annex III
a)
on the basis of medical, dental or veterinary prescription,
b)
for use in an animal by a person who treats that animal and who operates a veterinary skin pharmacist, or
c)
by a doctor in accordance with § 13 (1a) sentence 1
,
4.
Narcotic agents referred to in Annex III
a)
as a doctor, dentist or veterinarian in the context of the cross-border provision of services, or
b)
purchased from a medical, dental or veterinary prescription, and as a travel requirement
, executes or introduces
5.
commercial
a)
is involved in the transport of narcotic drugs between authorized participants in the carriage of narcotic drugs, or the storage and storage of narcotic drugs in connection with such transport or for an authorized participant in the -----------
b)
the dispatch of narcotic drugs between authorized participants in the transport of narcotics by others concerned or mediated; or
6.
Narcotics referred to in Annex I, II or III as a proband or patient in the course of a clinical trial or in cases of hardship pursuant to Section 21 (2) (6) of the Medicinal Products Act, in conjunction with Article 83 of Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 327, 28.3.2004, p. OJ L 136, 30.4.2004, p. 1).
(2) A permission in accordance with § 3 does not require federal and state authorities for the area of their official activities as well as the authorities responsible for the investigation of narcotics. (3) Those who do not have permission under paragraph 1 (1) and (2) The Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) has previously announced that it needs to participate in the transport of narcotics. The display must contain:
1.
the name and addresses of the scoreboard and the pharmacy or the veterinary medicinal products ' pharmacies,
2.
the date of issue and the issuing authority of the apothecary permit or of the Approbation as a veterinarian; and
3.
the date of commencement of participation in the movement of narcotic drugs.
The Federal Institute for Drugs and Medical Devices shall immediately inform the competent supreme state authority of the contents of the advertisements as far as they concern veterinary skin pharmacies. Unofficial table of contents

§ 5 Say of permission

(1) The permission in accordance with § 3 shall be refused if:
1.
it is not guaranteed that a person shall be appointed in the permanent establishment and, if there are other premises in non-neighbouring municipalities, in each of these premises a person responsible for the compliance with the whereas the applicant may take the place of a person in charge of anaesthesiological legislation and the instructions of the supervisory authorities (person responsible);
2.
the person in charge does not have the necessary expertise or is unable to meet the obligations imposed on him by the person concerned,
3.
where there are concerns about the reliability of the person responsible, the applicant, his or her legal representative or, in the case of legal persons or non-legal persons, associations of persons according to the law, the statutes, or company contract for the representation or management of authorized persons,
4.
appropriate spaces, facilities and safeguards are not available for participation in the transport of narcotic drugs or the preparation of preparations which have been carried out,
5.
there is no guarantee of the safety or control of the transport of narcotics or preparations of other preparations other than those referred to in points 1 to 4;
6.
the nature and purpose of the transport requested shall not, with the purpose of this law, ensure the necessary medical care for the population but, in addition, the abuse of narcotics or the improper manufacture of such products; to the extent to which it is possible to exclude preparations and the emergence or obtaining of a drug dependence, as far as possible, or
7.
If the submitted application documents are not submitted, a defect is not remedied within the time limit set (§ 8 para. 2).
(2) Permission may be refused if it precluded or because of the implementation of the international drug transfer agreements or decisions, orders or recommendations of intergovernmental bodies of narcotic control. Legal acts of the institutions of the European Union. Unofficial table of contents

§ 6 expertise

(1) Proof of the necessary expertise (Section 5 (1) no. 2) is provided
1.
in the case of the manufacture of narcotics or preparations which are excluded, which are medicinal products, by demonstrating the expertise referred to in Article 15 (1) of the Medicines Act,
2.
in the case of the manufacture of narcotic drugs which are not medicinal products, the certificate of a university degree in biology, chemistry, pharmacy, human or veterinary medicine completed after completing a scientific study examination and confirmation of at least one year's practical activity in the manufacture or testing of narcotic drugs,
3.
in the case of use for scientific purposes, the examination by the certificate of a study of biology, chemistry, pharmacy, human or veterinary medicine completed after a scientific university degree, and
4.
in all other cases, through the certificate of completed vocational training as a merchant in wholesale and foreign trade in the fields of chemistry or pharma and through the confirmation of at least one year's practical activity in the Anesthetic transport.
(2) The Federal Institute for Drugs and Medical Devices may, on a case-by-case basis, derogate from the requirements referred to in paragraph 1 of this Article if the safety and control of the transport of narcotic drugs or of the production of the Preparations are guaranteed. Unofficial table of contents

§ 7 Request

The application for the grant of a licence pursuant to § 3 shall be submitted in duplicate to the Federal Institute for Drugs and Medical Devices, which shall send a copy of the competent supreme state authority. The application must be accompanied by the following particulars and documents:
1.
the names, first names or the firm and the addresses of the applicant and those responsible,
2.
for those responsible, the evidence of the necessary expertise and explanations as to whether, and on the basis of what circumstances, they may be able to comply with the obligations imposed on them,
3.
a description of the location of the premises by location (if applicable, land name), road, house number, building and part of the building, and the construction of the building,
4.
a description of the existing safeguards against the removal of narcotic drugs by unauthorised persons;
5.
the nature of the movement of narcotics (Article 3 (1)),
6.
the nature and the estimated annual quantity of narcotic products to be produced or required;
7.
in the case of production (section 2 (1) (4)) of narcotic drugs or preparations excluded, a short description of the production process, specifying the type and quantity of the starting materials or preparations, the intermediate and final products, even if the starting materials or preparations, intermediate or final products are not anesthetic; in the case of preparations not divided, the percentages by weight, in the case of preparations which have been divided, the quantities by weight of the form each divided the narcotics and
8.
in the case of use for scientific or other purposes in the public interest, an explanation of the objective pursued, with reference to relevant scientific literature.
Unofficial table of contents

§ 8 Decision

(1) The Federal Institute for Drugs and Medical Devices shall decide within three months after receipt of the application for the grant of the permit. It shall inform the competent supreme authority immediately of the decision. (2) If the Federal Institute for Medicinal Products and Medical Devices gives the applicant the opportunity to remedy the deficiencies of the application, the provisions of paragraph 1 shall be referred to. period until the deficiencies or until the expiry of the time limit set in order to remedy the deficiencies are suspended. The inhibition begins with the day on which the applicant is sent the request to remedy the deficiencies. (3) The holder of the permit has any change in the information specified in § 7 of the Federal Institute for Drugs and Medical Devices without delay. In the event of an extension of the type of narcotic or narcotic movement, as well as changes in the person of the holder of the permit or the location of the premises, with the exception of a building, a new permit shall be granted. apply. In the other cases, permission is changed. The competent supreme state authority shall be informed immediately of the amendment of the permit. Unofficial table of contents

§ 9 Restrictions, freezing, conditions and conditions

(1) The authorization shall be limited to the extent necessary to ensure the safety and control of the transport of narcotic drugs or the preparation of preparations which have been carried out. In particular, it must regulate:
1.
the nature of the narcotics and the transport of narcotics,
2.
the estimated annual quantity and the stock of narcotic drugs,
3.
the location of the premises and
4.
the production process and the resulting starting, intermediate and final products, even if they are not anesthetic.
(2) permission may be granted
1.
for a limited period, subject to conditions, or subject to conditions, or
2.
after being granted in respect of the second sentence of paragraph 1, be amended or provided with other restrictions or conditions,
where this is necessary for the safety or control of the transport of narcotic drugs or preparations of the preparation of the preparations, or the authorization of the implementation of the international agreements on narcotic drugs or of decisions, orders or arrangements, or Recommendations of intergovernmental bodies to control narcotic drugs are contrary to, or are required by, acts of the institutions of the European Union. Unofficial table of contents

Section 10 Revocation and revocation

(1) The permission may also be revoked if no use has been made of it within a period of two calendar years. The deadline may be extended if a legitimate interest is credibly made. (2) The competent supreme state authority shall be immediately informed of the withdrawal or revocation of the permit. Unofficial table of contents

§ 10a Permission for the operation of drug consumption rooms

(1) A permit issued by the competent authority of the highest authority shall require the establishment of a facility in the premises of which there is an opportunity for the use of narcotic drugs which are not prescribed by medical practice and which are not prescribed by medical practice. provides or is granted (drug consumption room). Permission may be granted only if the State Government has regulated the conditions for grant in accordance with the conditions laid down in paragraph 2. (2) The State Governments are authorized to do so by means of a legal regulation. the conditions to be laid down for the granting of a permit referred to in paragraph 1. In particular, the rules must lay down the following minimum standards for the safety and control of the consumption of narcotic drugs in drug-consumption rooms:
1.
Appropriate factual equipment of the premises intended to serve as a drug consumption room;
2.
Ensure emergency medical emergency care;
3.
medical advice and assistance for the purposes of risk reduction in the consumption of narcotic drugs carried on by addicts;
4.
Placement of further and exit-oriented offers of counselling and therapy;
5.
measures to prevent criminal offences under this law in drug-consuming areas, except for the possession of narcotic drugs in accordance with Article 29 (1) sentence 1 (3) on own consumption in small quantities;
6.
necessary forms of cooperation with the local authorities responsible for public security and order in order to prevent, as far as possible, criminal offences in the immediate vicinity of the drug-consuming premises;
7.
the precise definition of the circle of authorised users of drug users, in particular with regard to their age, the nature of the narcotics carried along and the tolerated patterns of consumption; public or occasional users are of the opinion of the exclusion of use;
8.
a documentation and evaluation of the work in the drug-consuming areas;
9.
the permanent presence of personally reliable personnel in sufficient numbers to meet the requirements set out in points 1 to 7;
10.
Appointment of a competent person responsible for the compliance with the requirements set out in points 1 to 9, the conditions of the approval authority and the supervisory authority's orders (person responsible) and the persons responsible for the compliance with the requirements laid down in the above Obligations can be fulfilled all the time.
(3) For the permission procedure, § 7 sentence 1 and 2 Nos. 1 to 4 and 8, § § 8, 9 para. 2 and § 10 apply accordingly; in this case, the competent supreme state authority shall be replaced by the Federal Institute for Medicinal Products and Medical Devices, in each case, the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte). (4) , or in the case of direct consumption of the narcotic drugs, active assistance .

Third Section
Obligations in the field of narcotic drugs

Unofficial table of contents

Section 11 Imports, exports and transit

(1) In addition to the required permission in accordance with § 3 of the Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte), anyone who wants to import or export narcotics Narcotics may be subject to the scope of this Act only under the supervision of customs authorities without further residence or residence and without the use of the narcotic agent at any time during the course of the period of validity of the law. of the carrying out of the carrying out or of a third person is actually made available. Excluded preparations may not be exported to countries which have prohibited the import. (2) The Federal Government is authorized to regulate the procedure for the granting of the authorisation by means of a regulation without the consent of the Bundesrat. and provisions concerning the import, export and transit of goods, in so far as it is necessary to ensure the safety or control of the movement of narcotic drugs, the implementation of international instruments of narcotics of narcotic drugs or of acts of the institutions of the European Union is required. In particular,
1.
restricts the import, export or transit to certain narcotic drugs and quantities, and prohibits, in or through certain countries or from certain countries,
2.
Derogations from paragraph 1 for travel and rehearsals in the context of international cooperation are authorised,
3.
Rules on the carrying-out of narcotics by doctors, dentists and veterinarians in the context of the cross-border provision of services, and
4.
Form, content, production, issue and retention of the official forms to be used
. Unofficial table of contents

§ 12 levy and acquisition

(1) Narcotic drugs may only be delivered to:
1.
persons or associations of persons who are in possession of a licence pursuant to § 3 to be acquired, or who operate a pharmacy or a veterinary medicine home pharmacy,
2.
the authorities or bodies referred to in Article 4 (2) or (26);
3. (omitted) (2) In addition to the cases of § 4 (1) (1) (e), the donor shall immediately inform the Federal Institute for Medicinal Products and Medical Devices of any individual charge, indicating the acquirer and the type and quantity of the narcotic agent. report. The acquirer has to confirm receipt of the narcotics. (3) Paragraphs 1 and 2 shall not apply to the person who is receiving the narcotic drugs.
1.
Levy of narcotic drugs referred to in Annex III
a)
on the basis of medical, dental or veterinary prescription in the course of the holding of a pharmacy,
b)
in the context of the holding of a veterinary home mortgage for an animal treated by the operator of this skin pharmacist,
c)
by the doctor referred to in Article 13 (1a) sentence 1,
2.
the export of narcotic drugs and
3.
Levy and purchase of narcotic drugs between the authorities or bodies referred to in § 4 (2) or (26).
(4) The Federal Ministry of Health is authorized to regulate the procedure of the notification and the acknowledgement of receipt by means of a regulation without the consent of the Federal Council. In particular, it may regulate their form, content and storage as well as electronic transmission. Unofficial table of contents

§ 13 Enrollees and charges on prescription

(1) The narcotics referred to in Annex III may only be prescribed by doctors, dentists and veterinarians, and only by medical, dental or veterinary treatment, including the medical treatment of a veterinary surgeon. If they are used on the human or animal body or in the human or animal body, they may be administered or left to direct consumption or to another sentence for direct consumption or in accordance with the first sentence of paragraph 1a. The application shall not be justified, in particular, if the intended purpose can be achieved in other ways. The narcotics referred to in Annexes I and II may not be prescribed, administered or left to any other person for direct consumption or in accordance with the first sentence of paragraph 1a. (1a) To cover the non-suspendable need for narcotic drugs an outpatient palliative patient, the doctor may leave to that person the necessary narcotic drugs, referred to in Annex III, in the form of ready-to-use medicinal products, only if and as long as the patient's needs are met by a Cannot be covered in time; the maximum amount of transfer may not be covered do not exceed the three-day requirement. The need for the patient cannot be covered by a prescription in good time if the required narcotic agent is used.
1.
in the case of a pharmacy in the same district or in the same circular city or in neighbouring counties or towns not in stock, or is not available in good time for delivery, or
2.
even though it is available in a pharmacy in accordance with paragraph 1, or it cannot be procured in good time by the patient or the patient, because it is available in a timely manner or in good time for the delivery of the patient or the patient.
a)
these persons have to supply the patient on the spot or, because of their limited capacity, are unable to obtain the narcotic agent, or
b)
because of the nature and extent of his illness, the patient is not himself able to do so, and there are no persons who provide the patient.
The doctor must, on the basis of the fact that a situation is in accordance with the first sentence, ask a pharmacist who is ready for service in accordance with the second sentence of the second sentence of the second sentence, whether the necessary narcotic is in stock there or until when it is ready for delivery. The doctor must keep at least the following records of the conditions laid down in sentences 1 and 2 and the question referred to in the third sentence, and keep those records for three years from the date of release of the narcotic drugs:
1.
the name of the patient as well as the place, date and time of treatment,
2.
the name of the pharmacy and the pharmacist contacted or the person authorised to represent it;
3.
the name of the narcotic agent surveyed,
4.
the indication of the pharmacy, whether the narcotic is in stock at the time of the request or until when it is ready for delivery,
5.
the information on the facts which result from the existence of the conditions laid down in sentences 1 and 2.
The pharmacist or the person entitled to his/her representative must keep at least the following records of the question of a doctor treating in accordance with the first sentence, whether a certain narcotic agent is available or until when it is available for delivery. and these three years, calculated from the date of the request, shall be kept:
1.
the date and time of the request,
2.
the name of the doctor,
3.
the name of the narcotic agent surveyed,
4.
the indication to the doctor whether the narcotic is available at the time of the request or until when it is ready for delivery.
In the case of the leave referred to in the first sentence, the doctor shall inform the outpatient palliative patient or third party who is to be cared for about the proper use of the narcotic drugs and a written instruction manual (2) The narcotics prescribed in accordance with paragraph 1 may only be delivered in the course of the operation of a pharmacy and upon presentation of the prescribing. Diamorphine may only be delivered by the pharmaceutical operator and only to recognised bodies referred to in the second sentence of paragraph 3 (2) (2a) upon presentation of the prescribable. In the course of the establishment of a veterinary skin pharmacist, only the narcotic agents listed in Annex III may be released and only for use in the case of an animal treated by the operator of the home pharmacy. (3) The Federal Government is authorized to: by means of a legal regulation, with the consent of the Bundesrat, the prescribing of the narcotics referred to in Appendix III, their charge on the basis of a prescription and the recording of their whereabation and the stock of doctors, dentists, Veterinary surgeons, pharmacies, veterinary hospital pharmacy, hospitals, Animal clinics, old and nursing homes, hospices, facilities of specialized outpatient palliative care, facilities of the rescue services, facilities in which treatment with the substitution agent diamorphine takes place, and on for the safety or control of the carriage of narcotic drugs. In particular,
1.
the prescribable is restricted to certain preparations, purposes or quantities;
2.
the prescribing of substitution funds for drug addicts depended on the fulfilment of minimum requirements for the qualification of prescribers and the laying down of minimum requirements to the medical chambers,
2a.
the prescribations of diamorphine are authorised only in establishments which have been granted a permit by the competent State authority,
2b.
the minimum requirements for the equipment of the facilities in which the treatment with the substitution agent diamorphine is to take place,
3.
Notifications
a)
the prescribing physicians to the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) about the prescribing of a substitute for a patient in an anonymized form,
b)
the medical chambers of the Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte), which meet the minimum requirements laid down in point 2, and
Communications
c)
the Federal Institute for Medicinal Products and Medical Devices to the competent surveillance authorities and to the prescribing physicians about the patients who have already prescribed a substitution agent to another physician, in an anonymised form,
d)
the Federal Institute for Medicinal Products and Medical Devices to the competent surveillance authorities of the countries on doctors who meet the minimum requirements laid down in point 2,
e)
of the Federal Institute for Medicinal Products and Medical Devices to the Supreme State Health Authorities on the number of patients who have been prescribed a substitution agent, the number of doctors required to prescribe a substitution agent the number of physicians who have prescribed a substitution agent, the prescribed substitution agent and the type of prescription
as well as the nature of the anonymization, form and content of the notifications and communications,
4.
the form, content, production, issue, retention and return of the official form to be used for the prescribings and records of the whereabation and stock, and
5.
Exceptions to § 4 (1) (1) (c) for the equipment of commercial vehicle vessels shall be adopted.
For the procedure for the granting of a permit pursuant to the second sentence of the second sentence, the first sentence of § 7, second sentence, points 1 to 4, the first sentence of Article 8 (1), the second sentence and the third sentence of the first sentence of paragraph 3, the second paragraph of Article 9 and the second sentence of Article The Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte) is replaced by the competent national authority of the Federal Institute for Drugs The recipients referred to in the second sentence of paragraph 3 shall not use the data transmitted for a purpose other than those referred to in sentence 1. The Federal Institute for Medicinal Products and Medical Devices is acting in the exercise of the tasks assigned to it by means of a decree in accordance with the second sentence of the second sentence, as the institution of the respective competent country, which is the subject of the federal government; details Payment of expenses to the federal government shall be governed by agreement. Unofficial table of contents

Section 14 Labelling and advertising

(1) In the case of narcotics, the narcotic agents shall be labelled using the abbreviations listed in the annexes. The marking must be made in clearly legible writing, in German and in a permanent way. (2) The marking must also contain
1.
in the case of raw, uncleaned and undivided narcotics, the weight percentage and, in the case of narcotic drugs, the weight of the pure substance contained;
2.
in the case of narcotic containers and, where used, on the outer wrapping of substances and preparations not divided, the quantity of weight contained in the case of the preparations which have been divided; this shall not apply to: Storage containers in scientific laboratories as well as small containers and ampoules intended for delivery.
(3) Paragraphs 1 and 2 shall not apply to storage containers in pharmacies and veterinary medicinal products. (4) Paragraphs 1 and 2 shall also apply mutagenally to the name of narcotics, in catalogues, price lists, advertisements, or similar Printed products intended for the professional circles involved in the transport of narcotic drugs. (5) For narcotics referred to in Annex I, it is not allowed to advertise. Narcotics referred to in Annexes II and III may be advertised only in professional circles in industry and in trade and in persons and persons ' associations operating a pharmacy or a veterinary medicine house, for in Plant III also referred to narcotics in the case of doctors, dentists and veterinarians. Unofficial table of contents

§ 15 Safety measures

Persons participating in the trade in narcotic drugs shall keep the narcotics in their possession separately and shall secure them against unauthorised removal. The Federal Institute for Medicinal Products and Medical Devices may order precautionary measures in so far as it is necessary according to the nature or extent of the drug traffic, the degree of risk or the amount of the narcotic agents. Unofficial table of contents

§ 16 Destruction

(1) The owner of narcotic drugs which are no longer marketable shall destroy them at his expense in the presence of two witnesses in a manner that excludes any partial recovery of the narcotic drugs and the protection of Ensuring human health and the environment from harmful effects. The Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte-Bundesinstitut für Arzneimittel und Medizinprodukte), in the cases of § 19 (1) sentence 3, the competent authority of the country, to send the narcotics at its cost to these authorities for destruction. If an owner of the narcotics does not exist or is not to be identified, or the owner of his obligation to destroy or call for the submission of the narcotics pursuant to sentence 1 does not occur within a previously set Within three months, the authorities referred to in the first sentence shall take the measures necessary to destroy them. The owner or owner of the narcotic agent shall be obliged to issue the narcotic means to the persons responsible for the destruction or to tolerate the removal. (3) (3) (1) and (2) sentence 1 and 3 shall apply accordingly if the Owners do not want to remove any more needed narcotics. Unofficial table of contents

§ 17 Records

(1) The holder of a permit in accordance with § 3 shall be obliged to keep, separately for each establishment and any narcotics, the following records of each access and each departure:
1.
the date,
2.
the name or company and address of the supplier or the consignee, or any other origin or whereaby,
3.
the quantity received or the quantity received and the resulting stock;
4.
in the case of cultivation, in addition, the area under cultivation by location and size and the date of sowing,
5.
in the case of production, in addition to the indication of the narcotic agents used or produced, the substances not subject to the law or the preparations taken out in accordance with the nature and quantity and
6.
in the case of preparations by the manufacturer, the name or business name and address of the consignee.
In place of the records referred to in paragraph 6, the copies of the original invoices in which the preparations are marked may be kept on a continuous basis after the date of invoice. (2) The records in the records or quantities to be invoied
1.
in the case of substances and preparations not divided, the quantity by weight and
2.
in the case of divided preparations, the number of units.
(3) The records or copies of the invoice shall be kept for three years, from the last record or from the last invoice date, separately. Unofficial table of contents

Section 18 Notifications

(1) The holder of a licence pursuant to § 3 shall be obliged to report to the Federal Institute for Medicinal Products and Medical Devices separately for each establishment and for each narcotic, the respective quantity, which shall:
1.
has been obtained in the case of cultivation, indicating the area under cultivation by location and size,
2.
, broken down by source,
3.
has been used for the manufacture of other narcotics, broken down by these narcotic agents,
4.
has been used for the manufacture of substances not covered by this Act, broken down by these substances,
5.
the preparation of the preparations of the preparations, broken down by these preparations,
6.
, broken down by exporting country,
7.
, broken down by importing country,
8.
has been acquired,
9.
has been made,
10.
has been destroyed,
11.
has been used for purposes other than those indicated in points 1 to 10, broken down according to the intended uses; and
12.
was present at the end of the respective calendar half-year as a stock.
(2) The quantities to be reported in the notifications shall be:
1.
in the case of substances and preparations not divided, the quantity by weight and
2.
in the case of divided preparations, the number of units.
(3) The notifications referred to in paragraph 1 (2) to (12) shall be submitted to the Federal Institute for Medicinal Products and Medical Devices by 31 January and 31 July respectively for the last half-year period and the notification referred to in paragraph 1 (1) to 31 January for the past (4) For the notifications referred to in paragraph 1, the official forms issued by the Federal Institute for Drugs and Medical Devices shall be used.

Fourth Section
Monitoring

Unofficial table of contents

Section 19 Enforcement authority

(1) The transport of narcotic drugs and the preparation of the preparations taken out are subject to supervision by the Federal Institute for Drugs and Medical Devices. This body shall also be responsible for producing, issuing and evaluating the official forms prescribed for the prescription of narcotic drugs. The movement of narcotics in doctors, dentists and veterinarians, pharmaceutical companies in the case of the dispensing of diamorphine and in pharmacies and, in the case of § 4 (1) (1) (f), between pharmacies, veterinary medicinal products, Hospitals and veterinary clinics are subject to surveillance by the competent authorities of the countries. They also monitor compliance with the minimum standards set out in § 10a (2); the persons responsible for monitoring are entitled to the powers regulated in § § 22 and 24. (2) The Federal Institute for Drugs and Medical Devices is (3) The cultivation of farmed hemp within the meaning of point (d) of the derogation on cannabis (marijuana) in Annex I is subject to the supervision of the Federal Institute for Agriculture and Food. Article 45 (4), first subparagraph, and the Annex to the Commission Implementing Regulation (EU) No 809/2014 of 17 July 2014 laying down detailed rules for the application of Regulation (EU) No 1306/2013 of the European Parliament and of the Council as regards the Integrated management and control systems, rural development measures and cross-compliance (OJ C 139, 30.4.2004, p. 69), as amended, shall apply accordingly. In addition, the 2014 will apply accordingly. The Federal Agency for Agriculture and Food shall be entitled to the data transmitted to it by the competent national authorities in accordance with the rules of the Integrated Administration and Control System relating to the cultivation of hemp and to the results of the The use of the basic premium THC controls for the purpose of monitoring under this Act. Unofficial table of contents

§ 20 Special authorization for the case of a voltage or defence

(1) The Federal Government is authorized to amend, by means of a regulation without the consent of the Federal Council, this Act or the legal regulations adopted pursuant to this Act for defence purposes in order to ensure the medical care of the To ensure the population with narcotic drugs, if the safety and control of the movement of narcotic drugs or the preparation of the preparations of the drugs is guaranteed. In particular,
1.
Tasks of the Federal Institute for Medicinal Products and Medical Devices pursuant to this Act and legal regulations issued pursuant to this Act are transferred to the Federal Ministry,
2.
the transport of narcotic drugs and the preparation of preparations which have been carried out are adapted to the specific requirements referred to in the first sentence;
3.
Reports on stocks
a)
Anaesthesials,
b)
preparations excluded, and
c)
the starting materials or preparations required for the production of narcotic drugs, even if these are not narcotic agents,
shall be arranged. In addition, the legal regulation may require the stocks referred to in the second sentence of paragraph 3 to be made available to certain persons or bodies for the purpose of their submission. (2) The legal regulation referred to in paragraph 1 may only be made subject to the conditions laid down in the Article 80a (1) of the Basic Law. (3) (omitted) Unofficial table of contents

Section 21 Participation of other authorities

(1) The Federal Ministry of Finance and the customs offices designated by it shall cooperate in the supervision of the import, export and transit of narcotic drugs. (2) The Federal Ministry of Finance may, in agreement with the Federal Ministry of Finance, The officers of the Federal Police, who are entrusted with tasks of border protection in accordance with § 2 of the Federal Police Act, and in agreement with the Bavarian State Minister of the Interior, the officials of the Bavarian Border Police with the perception of tasks entrusted to the customs services referred to in paragraph 1. If the officials referred to in the first sentence are responsible for these tasks, Section 67 (2) of the Federal Police Act applies accordingly. (3) In the event of suspected violations of prohibitions and restrictions of this law, which result in the handling of the officers, the the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) immediately. Unofficial table of contents

Section 22 Monitoring measures

(1) The persons responsible for monitoring shall be entitled to:
1.
to consult the documents relating to the transport of narcotic drugs or the manufacture or manufacture of the following products on the market, and to make copies or copies thereof, insofar as they are intended for safety or control the transport of narcotic drugs or the preparation of preparations which have been carried out may be of importance,
2.
to request all necessary information from natural and legal persons and non-legal persons ' associations,
3.
To enter and visit land, buildings, parts of buildings, facilities and means of transport in which the transport of narcotic drugs or the preparation of the preparations taken is carried out, the persons responsible for such transport being carried out by the to be convinced that the rules on the transport of narcotics or the preparation of preparations which have been carried out are complied with. Whereas, in order to prevent urgent risks to public safety and public order, in particular where it is necessary to ensure that the control of the transport of narcotics or preparations of the preparation of such preparations is carried out, such premises may also be used; are to be entered outside the operating and business hours as well as for residential purposes; in this respect, the fundamental right to inviolability of the apartment (Article 13 of the Basic Law) is restricted. As far as industrial manufacturing and wholesale operations are concerned, the surveys shall normally be carried out every two years,
4.
provisional arrangements to the extent that it is necessary for the prevention of urgent risks to the safety or control of the transport of narcotic drugs or to the preparation of preparations of the general nature of the preparation of drugs. For the same purpose, they may also prohibit, in whole or in part, the further participation in the transport of narcotic drugs or the further production of preparations which have been carried out, and the stocks of narcotic drugs or the preparations of the preparations which have been removed. under official closure. The competent authority (Section 19 (1)) shall have a final decision to decide on the provisional arrangements within one month of the adoption of the provisional arrangements.
2. The competent authority may also arrange for measures pursuant to paragraph 1 (1) and (2) by written means. Unofficial table of contents

§ 23 sampling

(1) In so far as it is necessary for the implementation of the rules relating to the transport of narcotics or the preparation of the preparations of those preparations, the persons responsible for monitoring shall be entitled to rehearsals against the receipt of a certificate, in accordance with the conditions laid down in the To request or withdraw a selection for the purpose of the investigation. Unless expressly waived, a part of the sample or, if the sample is not partially or without endangering the purpose of the examination, is not part of the same quality, a second piece of the same kind as the sample (2) Withdrawal of rehearsals shall be officially closed or sealed. They shall be provided with the date of the sampling and the date of the day after which the closure or sealing shall be deemed to have been lifted. (3) Appropriate compensation shall be provided for samples taken, unless expressly stated to be dispensed with. Unofficial table of contents

§ 24 Dulunding and obligation to participate

(1) Each participant in the anesthesia transport or any producer of the preparations taken is obliged to tolerate the measures in accordance with § § 22 and 23 and to the persons responsible for the monitoring in the performance of their duties. assist, in particular, at the request of the bodies in which the transport of narcotic drugs or the preparation of the preparations has been carried out, to open the premises, buildings, spaces, containers and containers; To provide information and to inspect documents and to take samples (2) The information provided by the Commission may refuse access to such questions, the answers of which may be answered by him or one of his members of the risk of criminal proceedings, referred to in § 383 (1) (1) to (3) of the Code of Civil Procedure. It would suspend prosecution or proceedings in accordance with the Code of Administrative Offences. Unofficial table of contents

Section 24a Display of the cultivation of usage hemp

The cultivation of farmed hemp within the meaning of point (d) of the derogation for cannabis (marijuana) in Annex I shall be completed by 1 July of the cultivation year in three copies of the Federal Institute for Agriculture and Food in order to carry out its tasks in accordance with § 19 (3). The official form issued by the Federal Institute for Agriculture and Food is to be used for the display. The display must contain:
1.
the name, first name and address of the farmer and, in the case of legal persons, the name of the agricultural undertaking and of the legal representative;
2.
the member/cadastre number assigned to the agricultural enterprise by the competent professional association;
3.
the sown variety, accompanied by the official labels, provided that they have not been submitted under the basic premium schemes of the competent national authority,
4.
the sowing area in hectares and Ar, indicating the area identification number; if it does not exist, the cadastral number or other information identifying the sowing area may be indicated by the Federal Agency for Agriculture and Food , such as Gemarkung, Flur and Flurstück, for example, have been acknowledged.
The Federal Agency for Agriculture and Food shall immediately send a copy of the notification to the applicant without delay. It shall also send a copy of the notification to the competent police authorities and public prosecutors at their request, if this is necessary for the prosecution of criminal offences under this law. If the Federal Institute for Agriculture and Food provides evidence that the cultivation of farmed hemp does not meet the conditions laid down in point (d) of the derogation for cannabis (marijuana) in Annex I, it shall inform the local authorities of the situation in question. Public prosecutor's office. Unofficial table of contents

§ 25 Fees and charges

(1) The Federal Institute for Medicinal Products and Medical Devices charges fees and charges for its individual public services under this Act and the legal regulations issued pursuant to this Act. (2) The Federal Ministry is empowered to determine, by means of a regulation without the consent of the Federal Council, the chargeable cases in more detail and to provide fixed rates or framework rates.

Fifth Section
Rules applicable to authorities

Unofficial table of contents

Section 26 Bundeswehr, federal police, riot police and civil protection

(1) This Act, with the exception of the provisions relating to the authorization pursuant to § 3, shall apply to bodies serving the supply of narcotics to the Bundeswehr and the Federal Police, and to the storage of such supplies as referred to in Annex II or III. (2) In the areas of the Bundeswehr and the Federal Police, the enforcement of this law and the supervision of the trade in narcotic drugs are the responsibility of the respective competent authorities and Experts from the Federal Armed Forces and the Federal Police. In the field of civil protection, the Federal Ministry of Defence may, in agreement with the Federal Ministry of Defence, be responsible for the protection of the material. (3) The Federal Ministry of Defence may, in agreement with the Federal Ministry in individual cases Exceptions to this Act and the legal regulations issued pursuant to this Act permit, in so far as the international drug transfer income does not preclude this, and this is compelling reasons for the defence (4) This law shall apply with the exception of the provisions relating to: Permission in accordance with § 3 on the equipment used for the supply of narcotic drugs to the riot police of the countries, corresponding application. (5) (omitted) Unofficial table of contents

Section 27 Notifications and information

(1) The Federal Criminal Police Office shall report to the Federal Institute for Medicinal Products and Medical Devices annually until 31 March for the past calendar year the seizures of narcotics notified to him by type and quantity as well as, where appropriate, the further use of the narcotic agents. In the case of recovery, the name or business name and address of the acquirer shall be disclosed. (2) The authorities referred to in § 26 shall, at the request of the Federal Institute for Medicinal Products and Medical Devices, have a request for the marketing of narcotic drugs in (3) In criminal proceedings which have the subject of criminal offences under this Act, to be transmitted
1.
for the supervision and control of the movement of narcotic drugs in the persons and bodies referred to in Article 19 (1), third sentence, of the competent State authority, the final decision on the grounds that a penalty or a measure of the measure of the improvement and security, or the defendant has been acquitted of insolvency,
2.
for the purpose of carrying out the tasks referred to in Article 19 (1), second sentence, to the Federal Institute for Medicinal Products and Medical Devices in the case of the collection of the public lawsuit against doctors, dentists and veterinarians
a)
the indictup or an application to be sent to its place;
b)
the request for the adoption of a criminal order; and
c)
the decision closing the procedure on the ground; if an appeal has been rejected by that decision or is referred to in the contested decision, it shall also be communicated.
The transfer shall be initiated by the law enforcement authority or the law enforcement authority. (4) The decision closing the procedure on grounds in other criminal cases may be forwarded to the competent State authority if a connection between the In the case of a criminal offence, there is a need for a knowledge of the decision taken from the point of view of the notified body for the supervision of the movement of narcotic drugs, paragraph 3, first sentence, point 2 (c), second half-sentence. accordingly. Unofficial table of contents

Section 28 Annual report to the United Nations

(1) The Federal Government shall, by 30 June each year, reimburse the Secretary-General of the United Nations for an annual report on the implementation of the international drug transfer income in accordance with one of the following: United Nations Commission on Drugs and Drugs. The competent authorities of the Länder have an effect on the preparation of the report and submit their contributions to the Federal Institute for Drugs and Medical Devices by 31 March for the last calendar year. To the extent that the information required in the form cannot be determined, they are to be estimated. (2) The Federal Government is empowered to determine, by means of a regulation with the consent of the Bundesrat, which persons and entities are reporting, to reimburse statistical orders, other information and information necessary for the implementation of the international drug-addictive income. The Regulation may lay down rules on the manner, form, timing and beneficiaries of the notifications.

Sixth Section
Offences and regularties

Unofficial table of contents

§ 29 Crime

(1) With a custodial sentence of up to five years or a fine shall be punished, who
1.
Unauthorised to build, manufacture, trade with them, enter, carry out, sell, sell, sell, sell, sell or otherwise procrade in any other way, without trade,
2.
make an excluded preparation (§ 2 para. 1 no. 3) without permission in accordance with § 3 para. 1 no. 2,
3.
Without being in possession of a written permit for the acquisition,
4.
(dropped)
5.
, contrary to § 11 para. 1 sentence 2, narcotics,
6.
Contrary to § 13 para. 1, narcotics
a)
,
b)
to be administered or to be consumed for direct consumption,
6a.
, contrary to the first sentence of Article 13 (1) and of the first sentence of Article 13 (1), a method of
7.
contrary to Article 13 (2)
a)
Anesthesials in a pharmacy or veterinary skin pharmacist,
b)
Diamorphine as a Marketing Authorisation Holder
,
8.
Article 14 (5) for narcotic drugs,
9.
incorrect or incomplete information in order to obtain the prescription of a narcotic agent for himself or another animal or for an animal,
10.
give another opportunity to acquire or grant an unauthorised sale of narcotic drugs, provide such an opportunity for public or self-interest, or another for the unauthorised use of narcotic drugs ,
11.
, without the permission of Article 10a, give another opportunity to the unauthorised consumption of narcotics, or grant an opportunity for such consumption to be self-serving outside a body pursuant to § 10a. publicly,
12.
publicly, in a meeting or by publishing documents (Section 11 (3) of the Penal Code), to use narcotics which have not been prescribed by law to be prescribed,
13.
provides funds or other assets to another for an unlawful act according to points 1, 5, 6, 7, 10, 11 or 12;
14.
a legal regulation pursuant to § 11 para. 2 sentence 2 no. 1 or § 13 para. 3 sentence 2 no. 1, 2a or 5, insofar as it refers to this penal code for a certain amount of facts.
The transfer of sterile disposable syringes to narcotic agents and to public information on this shall not constitute a creation or public share of an opportunity for consumption as defined in the first sentence of the first sentence of 1. (2) In the cases referred to in the first sentence of paragraph 1 No. 1, 2, 5 or 6 (b) is an attempt to punish. (3) In particularly serious cases, the penalty is not less than one year. A particularly serious case is usually present when the perpetrator
1.
in the cases referred to in the first sentence of paragraph 1, 1, No.1, 5, 6, 10, 11 or 13,
2.
by one of the acts referred to in the first sentence of paragraph 1, point 1, 6 or 7, the health of a number of people is at risk.
(4) If the perpetrator is negligent in the cases referred to in the first sentence of the first sentence of paragraph 1, 2, 5, 6 (b), (10) or (11), the penalty shall be a custodial sentence of up to one year or a fine. (5) The court may, in accordance with paragraphs 1, 2 and 4, be punished. (6) The provisions of the first sentence of paragraph 1 are set out in the first sentence of paragraph 1, if the offender only builds, manufactures, imports, carries out, performs, acquires, acquires, acquires or possesses the narcotics in a small quantity. in so far as they concern the trading, giving or selling of the products, even if the In the case of substances or preparations which are not narcotic substances or preparations, they are to be issued as such.

Footnote

§ 29 (1) sentence 1, no. 1, 3, 5: In accordance with the decision formula, it is compatible with the GG. BVerfGE v. 9.3.1994 I 1207-2 BvL 43/92 u. a.- Unofficial table of contents

§ 29a Crime

(1) With imprisonment not under one year shall be punished, who
1.
as a person in excess of 21 years of anesthetic, he or she makes an unauthorised release to a person under the age of 18 years or, contrary to § 13 para. 1, he or she leaves it for direct consumption, or
2.
in the case of narcotic drugs in a small quantity unauthorised to trade, manufacture or supply them in a non-small quantity or possess them without having obtained them on the basis of a permit pursuant to Section 3 (1).
(2) In less serious cases, the penalty shall be a custodial sentence of three months to five years. Unofficial table of contents

§ 30 Crime

(1) With a custodial sentence not less than two years shall be punished who
1.
(§ 29 (1) sentence 1 (1)) and, in doing so, acts as a member of a gang which has committed itself to the continuing commission of such acts,
2.
in the case of section 29a (1) (1) of the commercial law,
3.
When it is being administered, it is administered to another or leaves it for immediate consumption, which causes it to be lightly killed, or
4.
It introduces anesthetic in a small amount of unallowed.
(2) In less serious cases, the penalty shall be a custodial sentence of three months to five years.

Footnote

§ 30 para. 1 no. 4: In accordance with the decision formula, it is compatible with the GG. BVerfGE v. 9.3.1994-2 BvL 43/92 u. a.- Unofficial table of contents

§ 30a Crime

(1) With a term of imprisonment of not less than five years, it shall be punished who creates, manufactures, trade with them in a small quantity unauthorised, executes them in or executes them (§ 29 para. 1 sentence 1 no. 1) and in doing so as a member of a gang which is linked to the continuing commission of such acts. (2) Likewise, it is punished who
1.
as a person over the age of 21 years, a person under the age of 18 years is destined to trade unauthorised by narcotics, to import, import, export, sell, sell or otherwise place on the market, or to enter into circulation, without any trade, or to enter into circulation or any other person under the age of 18 years. promote actions, or
2.
in the case of narcotic drugs in a small quantity unauthorised to trade, or, without trade, to carry out, carry out or confer without trade and, in so doing, carries out a firearm or other objects which, in its manner, have been violated by Persons are suitable and intended.
(3) In less serious cases, the penalty is imprisonment of six months to ten years. Unofficial table of contents

§ 30b Crime

§ 129 of the Criminal Code applies even if an association whose purposes or activities are directed to the unauthorised distribution of narcotics within the meaning of § 6 No. 5 of the Penal Code does not exist or not only domesticly. Unofficial table of contents

§ 30c Capital penalty

(1) In the cases of § 29 (1) Nos. 1, 5, 6, 10, 11 and 13, § 43a of the Criminal Code shall apply. This shall not apply in so far as the perpetrator sells, disposes, acquires, acquires or himself provides narcotics without any trade. (2) In the cases of § § 29a, 30, 30a and 30b § 43a of the Criminal Code shall apply. Unofficial table of contents

Section 31 Penal alleviation or decrimination of punishment

The court may mitigate the sentence in accordance with Section 49 (1) of the Criminal Code or, if the perpetrator has not had a custodial sentence of more than three years, depart from punishment if the perpetrator
1.
by a voluntary revelation of his knowledge, has contributed significantly to the fact that a criminal offence could be uncovered in accordance with § § 29 to 30a, which is related to his deed, or
2.
His or her knowledge is voluntarily disclosed to a department in good time that a criminal offence pursuant to Section 29 (3), § 29a (1), § 30 (1), § 30a (1), which is connected with his deed and whose planning he knows, can still be prevented.
If the perpetrator was involved in the act, his contribution to the Enlightenment according to the first sentence of 1 (1) must extend beyond his own contribution to the crime. § 46b (2) and (3) of the Penal Code shall apply accordingly. Unofficial table of contents

§ 31a Abvision of the persecution

(1) Where the proceedings are subject to an infringement pursuant to Article 29 (1), (2) or (4), the prosecution shall be able to depart from the prosecution if the perpetrator's guilt is to be considered low, there is no public interest in the prosecution, and the offender only builds, manufactures, carries out, carries out, performs, acquires, acquires or possesses in some other way the narcotics for own consumption in small quantities. The persecution is to be dissected if the perpetrator in a drug consumption room has a small quantity of narcotic drugs only for self-consumption, which can be tolerated in accordance with § 10a, without at the same time in possession of a written permission for (2) If the action has already been filed, the court may, with the consent of the Public Prosecutor's Office and the accused person, cease the proceedings in any state of the proceedings under the conditions set out in paragraph 1. The consent of the accused is not required if the main hearing cannot be carried out on the grounds stated in § 205 of the Code of Criminal Procedure or in the cases of § 231 (2) of the Code of Criminal Procedure and § § 232 and 233 of the Criminal procedure is carried out in his absence. The decision shall be taken by decision. The decision shall not be countervailable. Unofficial table of contents

§ 32 Administrative Offences

(1) Contrary to the law, those who intentionally or negligently act
1.
Contrary to § 4 (3) sentence 1, the participation in the movement of narcotics is not indicated,
2.
in an application pursuant to § 7, also in conjunction with § 10a (3) or § 13 (3) sentence 3, makes incorrect information or adds incorrect documents,
3.
Contrary to § 8 (3) sentence 1, also in conjunction with Section 10a (3), a change is not correct, not fully or not immediately communicated,
4.
a fully-fledgable edition in accordance with section 9 (2), also in conjunction with section 10a (3), contrary to the law
5.
, contrary to Section 11 (1), sentence 1 of a narcotic system, which is not approved or executed,
6.
a legal regulation in accordance with § 11 paragraph 2 sentence 2 no. 2 no. 2 to 4, § 12 para. 4, § 13 para. 3 sentence 2 Nos. 2, 3 or 4, § 20 para. 1 or § 28 para. 2, insofar as it refers to this fine for a certain amount of facts,
7.
, contrary to Section 12 (1) of the Law of Narcotics, or contrary to Section 12 (2), the delivery or acquisition does not report correctly, in whole or in part, or does not confirm the receipt without delay, or
7a.
is not asking a pharmacy in good time or in good time, contrary to the third sentence of Article 13 (1a),
7b.
, contrary to Article 13 (1), sentence 4 or 5, a record does not, either correctly or incompletely, or does not hold a record or not, or not, at least three years,
8.
Contrary to Article 14, para. 1 to 4, non-narcotic drugs are not marked in accordance with the rules
9.
an enforceable arrangement in accordance with § 15 sentence 2,
10.
Contrary to § 16 para. 1, narcotics are not destroyed, a record is not made or it is not kept, or contrary to § 16 para. 2 sentence 1 narcotics, not sent for destruction, also in connection with § 16 para. 3,
11.
, contrary to § 17 para. 1 or 2, records are not kept, not properly or incompletely, or are not kept in keeping with § 17 para. 3 records or accounting transcripts,
12.
Contrary to § 18 (1) to 3 notifications, not correct, not fully or not reimbursed in good time,
13.
Contrary to Article 24 (1), it does not comply with a duty of duty or obligation to comply with the law,
14.
Contrary to § 24a, the cultivation of usage hemp is not displayed correctly, is not displayed in full or in time, or
15.
It shall be placed in a postal consignment, although such dispatch shall be prohibited by the Universal Postal Agreement or by an agreement of the Universal Postal Association; the secrecy of mail pursuant to Article 10 (1) of the Basic Law shall be subject to persecution and prosecutions inasmuch as of regulariness.
(2) The administrative offence can be punished with a fine of up to twenty-five thousand euros. (3) The Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) is the administrative authority within the meaning of Section 36 (1) (1) of the Law on Administrative Offences, insofar as the law is executed by him, in the case of § 32 paragraph 1 No. 14 the Federal Institute for Agriculture and Food. Unofficial table of contents

Section 33 Extended decay and confiscation

(1) § 73d of the Criminal Code shall apply
1.
in the cases referred to in Article 29 (1), first sentence, No. 1, 5, 6, 10, 11 and 13, provided that the offender is acting on a commercial basis, and
2.
in the cases of § § 29a, 30 and 30a.
(2) Items to which a criminal offence relates in accordance with § § 29 to 30a or an administrative offence pursuant to § 32 may be drafted. Section 74a of the Criminal Code and Section 23 of the Law on Administrative Offences shall apply. Unofficial table of contents

Section 34 Management supervision

In the cases of § 29 para. 3, § § 29a, 30 and 30a, the court may order management supervision (Section 68 (1) of the Penal Code).

Seventh Section
Offenders-dependent offenders

Unofficial table of contents

Section 35 Reposition of the enforcement of the sentence

(1) If a person has been sentenced to a custodial sentence of not more than two years for a criminal offence and results from the reasons for the judgment, or if it is otherwise established that he has committed the act on the basis of a dependence on narcotics, it may be possible to: The executing authority, with the consent of the court of the first appeal, shall return the execution of the sentence, a criminal law or the measure of accommodation in an equalising institution for a maximum of two years if the convicted person is because of his dependence on his rehabilitation , or agrees to submit to such a subject, and the commencement thereof is guaranteed. The treatment also applies to the stay in a state-approved institution, which serves to remedy the dependence or to counteract reliance. (2) Against the refusal of the consent by the court of the first The enforcement authority shall submit the appeal to the enforcement authority in accordance with the second section of the third book of the Code of Criminal Procedure. The convicted person may contest the denial of this consent only together with the rejection of the deferment by the executing authority in accordance with § § 23 to 30 of the Introductory Act to the Law Constitutional Law. In this case, the Oberlandesgericht also decides on the refusal of consent; it may grant the consent itself. (3) Paragraph 1 shall apply accordingly if:
1.
has been recognized for an overall custodial sentence of not more than two years, or
2.
has been recognized for a custodial sentence or a total custodial sentence of more than two years and a sentence to be carried out does not exceed two years of imprisonment or the total custodial sentence
and in other respects, the conditions set out in paragraph 1 are fulfilled for the majority of the offences which have been assigned to them. (4) The convicted person shall be obliged to provide proof of his or her condition at the time of the enforcement of the sentence of the executing authority. to provide admission and the continuation of the treatment; the persons or entities treating the treatment shall notify the executing authority of termination of the treatment. (5) The enforcement authority shall revoke the deferment of enforcement; if the treatment is not started or is not continued and is not it is to be expected that the convicted person shall start or resume treatment of the same species as soon as possible, or if the convicted person does not provide the proof required under paragraph 4. The revocation may be waited if the convicted person subsequently proves that he is in treatment. A revocation pursuant to the first sentence shall not preclude the revocation of enforcement. (6) The revocation of enforcement shall also be revoked if:
1.
in the case of subsequent formation of a total penalty, the execution of such penalties shall not also be deferred in conjunction with paragraph 3, or
2.
a further sentence of imprisonment or a detention order to be completed against the convicted person is to be completed.
(7) If the executing authority has withdrawn the revocation, it shall be entitled to issue an arrest warrant for the execution of the custodial sentence or of the accommodation in a deprivation institution. The decision of the court of the first legal proceedings may be brought against the revocation. The continuation of enforcement shall not be inhibited by the appeal of the Court. Section 462 of the Code of Criminal Procedure shall apply accordingly. Unofficial table of contents

Section 36 Invoice and penalty suspension for parole

(1) Where enforcement has been completed and the convicted person has been treated in a state-approved institution, the time of his/her stay in that institution shall be punishable by the convicted person until two-thirds of the penalty has been settled as a result of the offsetting. The court of law shall at the same time take the decision on the validity of the invoice with the consent of Section 35 (1). If two-thirds of the penalty is settled by the offsetting or if a treatment is no longer necessary in the institution at an earlier date, the court shall suspend the execution of the sentence of the sentence on probation as soon as this is carried out under the conditions laid down in to take account of the security interest of the general public. (2) Where enforcement has been completed and the convicted person has been subject to his dependence on a treatment other than that referred to in paragraph 1, he shall: the court shall suspend the execution of the custodial sentence or of the criminal law (3) If the convicted person has, in fact, subjected himself to a treatment of his dependence, the court may, if the convicted person has been treated, the person who has been sentenced to the conditions laid down in the first sentence of paragraph 1 shall not be fulfilled, order that the period of treatment shall be counted wholly or partly on the penalty if, having regard to the requirements laid down by the treatment to the convicted person, that period of treatment shall be taken into account: (4) § § 56a to 56g and 57 (5) sentence 2 of the Penal Code shall apply accordingly. (5) The decisions referred to in paragraphs 1 to 3 shall be taken by the court of the first legal proceedings without oral proceedings by decision. The executing authority, the convicted person and the persons or entities treating them shall be heard. An immediate complaint is possible against the decisions. In the case of the decisions referred to in the third sentence of paragraph 1 and in accordance with paragraph 2, Section 454 (4) of the Code of Criminal Procedure shall apply accordingly; the instruction on the suspension of the criminal proceedings shall be issued by the court. Unofficial table of contents

Section 37 Abvision of the collection of the public action

(1) If a accused person is suspected of having committed a criminal offence on the basis of a drug addiction, and if no higher penalty than a custodial sentence of up to two years is to be expected, the Public Prosecutor's Office may, with the consent of the for the opening of the main proceedings, provisionally refrain from the imposition of the public action if the accused proves that he is subject to the treatment referred to in Article 35 (1), and his/her dependence on the proceedings, Resocialization is to be expected. The Public Prosecutor's Office shall determine the dates on which the accused has to prove the continued duration of the treatment. The procedure shall be continued if:
1.
the treatment is not continued until the end of the treatment,
2.
the accused does not carry out the proof referred to in the second sentence,
3.
the accused commits an offence and thereby shows that the expectation which was based on the imposition of the public action has not been fulfilled, or
4.
in the light of new facts or evidence, a term of imprisonment of more than two years is to be expected.
In the cases referred to in sentence 3 (1), (2), the continuation of the procedure may be waiver if the accused subsequently proves that he is continuing to be treated. The action can no longer be pursued if the proceedings are not continued within two years. (2) If the action has already been filed, the court may, with the consent of the Public Prosecutor's Office, the proceedings until the end of the main hearing, in The actual findings can be examined for the time being, provisionally. The decision shall be taken by means of an indisputable decision. The provisions of the second sentence of paragraph 1 shall apply accordingly. It is also indisputable that the procedure is not continued (paragraph 1). 1 sentence 5). (3) The regulations made in § 172 (2) sentence 3, § 396 (3) and § 467 (5) of the Code of Criminal Procedure to § 153a of the Code of Criminal Procedure apply accordingly. Unofficial table of contents

§ 38 Young people and adolescents

(1) In the case of sentencing to juvenile punishment, § § 35 and 36 shall apply mutatily. In addition to the commitment of the young person in accordance with § 35 (1) sentence 1, the consent of the legal guardian and the legal representative is also required. In the case of § 35 para. 6 sentence 2, § 83 para. 2 no. 1, para. 3 sentence 2 of the juvenile justice act shall apply mutationally. By way of derogation from Section 36 (4), § § 22 to 26a of the Juvenile Justice Act shall apply accordingly. In addition to Section 454 (4) of the Code of Criminal Procedure, the decisions pursuant to Section 36 (1) sentence 3 and Section 2 shall apply in addition to § § 58, 59 (2) to (4) and § 60 of the Juvenile Justice Act. (2) § 37 applies mutationally to adolescents and adolescents.

Eighth section
Transitional and final provisions

Unofficial table of contents

Section 39 Transitional regime

Establishments in whose premises the consumption of narcotic drugs which have been carried along and which have not been prescribed for medical treatment have been tolerated before 1 January 1999 shall be allowed to continue without the authorisation of the competent supreme state authority, if not later than 24 months after the entry into force of the Third BtMG Amendment Act of 28 March 2000 (BGBl. 302), a legal regulation pursuant to Section 10a (2) and a request for permission pursuant to Section 10a (1) of this Regulation shall be made. Pending the indisputable decision on an application, these institutions may only continue to be operated in so far as the requirements of Section 10a (2) or of a decree law adopted pursuant to this provision are fulfilled. Section 29 (1), first sentence, No. 10 and 11 shall also apply to bodies referred to in the first sentence. Unofficial table of contents

Section 39a Transitional regulation on the occasion of the law amending pharmaceutical and other provisions

For a person who does not have the expertise in accordance with § 5 (1) (2), but meets the requirements of § 141 (3) of the German Medicines Act on 22 July 2009, proof of the necessary expertise in accordance with § 6 (1) (1) shall be deemed to be valid. provided. Unofficial table of contents

§ § 40 and 40a (subject-free)

Unofficial table of contents

Section 41

(dropped) Unofficial table of contents

Annex I (to § 1 (1))
(non-marketable narcotics)

(Fundstelle: BGBl. I 2001, 1180-1186;
with regard to of the individual amendments. Footnote)

Column 1 contains the International Nonproprietary Names (INN) of the World Health Organization. In the name of a substance, the INN takes precedence over all other names.
Column 2 contains other non-protected fabric names (abbreviated names or trivial names). If an INN does not exist for a substance, its unique label can be used to use the name in bold in this column. All other non-bold names are not scientifically clear. They must therefore be used in conjunction with the designation in column 3.
Column 3 contains the chemical substance name according to the nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no name is listed in column 1 or 2, then the column 3 is to be used.
INN other unprotected or trivial names chemical names (IUPAC)
Acetorphine - {4 ,5α-epoxy-7α-[(R) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-6, 14-ethenomorphinan-3-yl} acetate
- Acetyldihydrocodeine (4 ,5α-epoxy-3-methoxy-17-methylmorphinan-6α-yl) acetate
Acetylmethadol - (6-Dimethylamino-4,4-diphenyl-heptane-3-yl) acetate
- Acetyl-α-methylfentanyl N-phenyl-N-[1-(1-phenyl-propan-2-yl)-4-piperidyl] acetamide
- - 4-Allyloxy-3,5-dimethoxy-phenethylazane
Allyl prodin - (3-Allyl-1-methyl-4-phenyl-4-piperidyl) propionate
Alphacetylmethadol - [(3R, 6R) -6-dimethylamino-4,4-diphenylheptan-3-yl] acetate
alphameprodin - [(3RS, 4SR) -3-ethyl-1-methyl-4-phenyl-4-piperidyl] propionate
Alphamethadol - (3R, 6R) -6-dimethylamino-4,4-diphenylheptan-3-ol
Alphaprodin - [(3RS, 4SR) -1,3-dimethyl-4-phenyl-4-piperidyl] propionate
- 5-(2-aminopropyl) indole
(5-IT)
1-(1H-indol-5-yl) propane-2-amine
Anileridin - Ethyl [ 1-(4-aminophenethyl)-4-phenyl-piperidine-4-carboxylate)
- BDB 1-(1,3-Benzodioxol-5-yl) butan-2-ylazane
Benzethidine - Ethyl { 1-[2-benzyloxy) ethyl]-4-phenyl-piperidine-4-carboxylate
Benzfetamine Benzphetamine (benzyl) (methyl) (1-phenylpropan-2-yl) azan
- - 1-(1,3-Benzodioxol-5-yl) -2-(pyrrolidin-1-yl) propan-1-one
- Benzyl fentanyl N-(1-benzyl-4-piperidyl)-N-phenyl-propanamide
- Benzylmorphine 3-Benzyloxy-4, 5α-epoxy-17-methylmorphin-7-en-6α-ol
Betacetylmethadol - [(3S, 6R) -6-dimethylamino-4,4-diphenylheptan-3-yl] acetate
Beta-meprodine - [(3RS, 4RS) -3-ethyl-1-methyl-4-phenyl-4-piperidyl] propionate
Betamethadol - (3S, 6R) -6-dimethylamino-4,4-diphenylheptan-3-ol
Beta-prodin - [(3RS, 4RS) -1,3-dimethyl-4-phenyl-4-piperidyl] propionate
Bezitramid - 4-[4-(2-Oxo-3-propionyl-2,3-dihydrobenzimidazol-1-yl) piperidino] -2,2,-diphenyl-butenitrile
- 25B-NBOMe
(2C-B-NBOMe)
2-(4-Bromo-2,5-dimethoxyphenyl) -N-[(2-methoxyphenyl) methyl] ethanamine
Brolamfetamine Dimethoxybromamfetamine (DOB) (RS)-1-(4-bromo-2,5-dimethoxy-phenyl)-propane-2-ylazane
- Bromodimethoxyphenethylamine (BDMPEA) 4-bromo-2,5-dimethoxyphenethyl-azan
- Cannabis
(marijuana, plants and plant parts of plants belonging to the genus Cannabis)
-
-except
a) the seed of which, unless it is intended for illicit cultivation,
b) if they come from cultivation in countries of the European Union with certified seed of varieties which, on 15 March of the crop year in the Annex to the Commission's Regulation (EU) No 639/2014 of 11 March 2014, Regulation (EU) No 1307/2013 of the European Parliament and of the Council laying down rules for direct payments to farmers under support schemes of the common agricultural policy and amending Annex X to the , Regulation (EC) No 1), the common catalogue of varieties of agricultural plant species referred to in the current version is listed, or its tetrahydrocannabinol content does not exceed 0.2 per cent and the traffic with them is not greater than (except for the cultivation) exclusively for commercial or scientific purposes, which exclude any abuse for noise purposes,
c) if they are planted as a protective strip during beet breeding and destroyed before flowering,
d) if they are cultivated by agriculture undertakings which fulfil the conditions laid down in Article 1 (4) of the Law on the Pensions of Farmers, with the exception of forestry, garden and winegrowing enterprises, fish farming, the pond economy, the beekeeping sector, the inland fishing and migrant workers, or the granting of aid under Regulation (EU) No 1307/2013 of the European Parliament and of the Council of 17 December 2013 laying down rules on direct payments holders of agricultural holdings under the support schemes of Common agricultural policy and repealing Council Regulation (EC) No 637/2008 and Council Regulation (EC) No 73/2009 (OJ L 145, 31.5.2009, p. 608), as amended, and the cultivation of varieties exclusively from certified seed of varieties which, on 15 March of the crop year in the Regulation referred to in Article 9 of the Delegated Regulation (EU) No 639/2014 referred to as the common catalogue of varieties of agricultural plant species referred to in the following (the hemp); or
e) on the purposes referred to in Annexes II and III,
- Cannabis resin
(Hashish, the secreted resin of the plant belonging to the genus Cannabis)
-
Carfentanil - Methyl [1-phenethyl-4-(N-phenyl-propanamido)-piperidine-4-carboxylate]
Cathinon - (S) -2-amino-1-phenylpropan-1-one
- 2C-C 2-(4-chloro-2,5-dimethoxyphenyl) ethanamine
- 2C-D
(2C-M)
2-(2,5-Dimethoxy-4-methylphenyl) ethanamine
- 2C-E 2-(4-ethyl-2,5-dimethoxyphenyl) ethanamine
- 2C-l 4-lod-2,5-dimethoxyphenethyl-azan
- 6-Cl-MDMA [1-(6-chloro-1,3-benzodioxol-5-yl) propan-2-yl] (methyl) azan
Clonitazen - {2-[2-(4-chlorobenzyl) -5-nitrobenzimidazol-1-yl] ethyl} diethylazane
- 25C-NBOMe
(2C-C-NBOMe)
2-(4-chloro-2,5-dimethoxyphenyl) -N-[(2-methoxyphenyl) methyl] ethanamine
- Codeine-N-oxide 4,5α-epoxy-3-methoxy-17-methylmorphine-7-ene-6α-ol-17-oxide
Codoxim - (4 ,5α-Epoxy-3-methoxy-17-methylmorphinan-6-ylidene-aminooxy) acetic acid
- 2C-P 2-(2,5-Dimethoxy-4-propylphenyl) ethanamine
- 2C-T-2 4-ethylsulfanyl-2,5-dimethoxy-phenetylazane
- 2C-T-7 2,5-Dimethoxy-4-(propylsulfanyl) phenethylazane
Desomorphine Dihydrodesoxymorine 4,5α-Epoxy-17-methyl-morphinan-3-ol
Diampromide - N-{2-[(methyl) (phenetyl) amino] propyl} -N-phenylpropanamide
- Diethoxybromamfetamine 1-(4-Bromo-2,5-diethoxyphenyl) propan-2-ylazane
Diethylthiambuten - Diethyl (1-methyl-3,3-di-2-thienylallyl) azan
- N, N-diethyltryptamine (diethyltryptamine, DET) Diethyl [2-(indol-3-yl) ethyl] azan
- Dihydroetorphine
(18 ,19-Dihydroetorphine)
(5R, 6R, 7R, 14R) -4, 5α-epoxy-7α-[(R) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-6, 14-ethanomorphinan-3-ol
Dimenoxadol - (2-Dimethylaminoethyl) [(ethoxy) (diphenyl) acetate]
Dimepheptanol Methadol 6-Dimethylamino-4,4-diphenyl-heptane-3-ol
- Dimethoxyamfetamine (DMA) 1-(2,5-dimethoxyphenyl) propan-2-ylazane
- Dimethoxyethylamfetamine (DOET) 1-(4-ethyl-2,5-dimethoxyphenyl) propan-2-ylazane
- Dimethoxymethamfetamine (DMMA) 1-(3,4-dimethoxyphenyl) -N-methylpropan-2-amine
- Dimethoxymethylamfetamine (DOM, STP) (RS) -1-(2,5-dimethoxy-4-methylphenyl) propan-2-ylazane
- Dimethylheptyltetrahydrocannabinol (DMHP) 6,6,9-Trimethyl-3-(3-methyl-octane-2-yl)-7,8,9, 10-tetra-hydro-6H-benzo (c) chromen-1-ol
Dimethylthiambuten - Dimethyl (1-methyl-3,3-di-2-thienylallyl) azan
- N, N-dimethyltryptamine (dimethyltryptamine, DMT) [2-(Indol-3-yl) ethyl] dimethyl-azan
Dioxaphetyl butyrate - Ethyl-(4-morpholino-2,2-diphenylbutanoate)
Dipipanon - 4,4-diphenyl-6-piperidinoheptan-3-one
- DOC 1-(4-chloro-2,5-dimethoxyphenyl) propan-2-ylazane
Drotebanol - 3,4-Dimethoxy-17-methyl-morphinan-6ß, 14-diol
- N-ethylbuphedrone
(NEB)
2-(Ethylamino) -1-phenylbutan-1-one
- 4-Ethylmethcathinone
(4-EMC)
1-(4-ethylphenyl) -2-(methylamino) propan-1-one
Ethylmethylthiambuten - (ethyl) (methyl) (1-methyl-3,3-di-2-thienylallyl) azan
- Ethyl
(bk-MDEA, MDEC)
1-(1,3-Benzodioxol-5-yl) -2-(ethylamino) propan-1-one
- Ethylpiperidylbenzilate (1-ethyl-3-piperidyl) benzilate
Eticyclidine PCE (ethyl (1-phenylcyclohexyl) azan
Etonitazen - {2-[2-(4-ethoxybenzyl) -5-nitrobenzimidazol-1-yl] ethyl} diethylazane
Etoxeridin - Ethyl {1-[2-(2-hydroxyethoxy) ethyl] -4-phenylpiperidine-4-carboxylate}
Etryptamine α-ethyltryptamine 1-(Indol-3-yl) butan-2-ylazane
- FLEA N-[1-(1,3-Benzodioxol-5-yl)-propane-2-yl]-N-methyl-hydroxylamine
- 4-Fluoramfetamine (4-FA, 4-FMP) (RS) -1-(4-Fluorophenyl) propane-2-amine
- ρ-Fluorfentanyl N-(4-Fluorophenyl) -N-(1-phenethyl-4-piperidyl) propanamide
- 2-Fluoromethamfetamine
(2-FMA)
1-(2-Fluorophenyl) -N-methylpropan-2-amine
- 3-Fluoromethamfetamine
(3-FMA)
1-(3-Fluorophenyl) -N-methylpropan-2-amine
Furethidin - Ethyl { 4-phenyl-1-[2-tetra-hydrofurfuryloxy) ethyl] piperidine-4-carboxylate.
- Heroin
(Diacetylmorphine, diamorphine)-excluding diamorphine to the purposes specified in Annexes II and III,
[(5R, 6S)-4,5-Epoxy-17-methyl-morphin-7-en-3,6-diyl] diacetate
Hydromorphinol 14 -Hydroxydihydromorphine 4,5α-Epoxy-17-methyl-morphinan-3, 6α, 14-triol
- N-hydroxyamfetamine (NOHA) N-(1-phenylpropan-2-yl) hydroxylamine
- ß-hydroxyfentanyl N-[1-(2-hydroxy-2-phenyl-ethyl)-4-piperidyl]-N-phenylpropanamide
- Hydroxymethylenedioxyamfetamine (N-hydroxy-MDA, MDOH) N-[1-(1,3-benzodioxol-5-yl) propan-2-yl] hydroxylamine
- β-hydroxy-3-methyl-fentanyl (Ohmefentanyl) N-[1-(2-hydroxy-2-phenyl-ethyl)-3-methyl-4-piperidyl]-N-phenylpropanamide
Hydroxypethidine - Ethyl [4-(3-hydroxyphenyl) -1-methylpiperidine-4-carboxylate]
- 25I-NBOMe
(2C-I-NBOMe)
2-(4-lod-2,5-dimethoxyphenyl) -N-[(2-methoxyphenyl) methyl] ethanamine
Lefetamine SPA [(R) -1,2-Diphenylethyl] dimethylazane
Levomethorphan - (9R, 13R, 14R) -3-methoxy-17-methylmorphinan
Levophenacylmorphan - 2-[(9R, 13R, 14R)-3-hydroxy-morphinan-17-yl]-1-phenyl-ethanone
Lofentanil - Methyl [(3R, 4S)-3-methyl-1-phenethyl-4-(N-phenyl-propanamido)-piperidin-4-carboxylate]
Lysergid N, N-Diethyl-D-lysergamide (LSD, LSD-25) N, N-diethyl-6-methyl-9, 10-didehydroergoline-8β-carboxamide
- MAL 3,5-Dimethoxy-4-(2-methyl-allyloxy) phenethylazane
- MBDB [1-(1,3-Benzodioxol-5-yl) butan-2-yl] (methyl) azan
- Mebroqualon 3-(2-bromophenyl)-2-methyl-quinazolin-4 (3H)-one
Mecloqualon - 3-(2-Chlorophenyl)-2-methyl-quinazolin-4 (3H)-one
- Mescalin 3,4,5-Trimethoxyphenethylazane
Metazocin - 3,6,11-trimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
- Methcathinon (Ephedron) 2-methylamino-1-phenylpropan-1-one
- Methiopropamine (MPA) N-methyl-1-(thiophen-2-yl) propan-2-amine
- methoxetamine (MXE) 2-(Ethylamino) -2-(3-methoxyphenyl) cyclohexanone
- Methoxyamfetamine (PMA) 1-(4-Methoxyphenyl) propan-2-ylazane
- 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT) Diisopropyl [2-(5-methoxyindol-3-yl) ethyl] azan
- 5-methoxy-DMT (5-MeO-DMT) [2-(5-Methoxyindol-3-yl) ethyl] dimethylazane
- - (2-methoxyethyl) (1-phenyl-cyclohexyl) azan
- Methoxymetamfetamine (PMMA) [1-(4-Methoxyphenyl) propan-2-yl] (methyl) azan
- Methoxymethylenedioxyamfetamine (MMDA) 1-(7-methoxy-1,3-benzodioxol-5-yl) propan-2-ylazane
- - (3-methoxypropyl) (1-phenyl-cyclohexyl) azan
- Methylaminorex (4-Methylaminorex) 4-Methyl-5-phenyl-4,5-dihydro-1,3-oxazol-2-ylazane
- 4-Methylbuphedrone
(4-MeMABP)
2-(Methylamino) -1-(4-methylphenyl) butan-1-one
Methyldesorphine - 4,5α-Epoxy-6, 17-dimethyl-morphine-6-en-3-ol
Methyldihydromorphine - 4,5α-Epoxy-6, 17-dimethyl-morphinan-3,6α-diol
- Methylenedioxyethylamfetamine (N-ethyl-MDA, MDE, MDEA) [1-(1,3-Benzodioxol-5-yl) propan-2-yl] (ethyl) azan
- Methylenedioxymetamfetamine (MDMA) [1-(1,3-Benzodioxol-5-yl) propan-2-yl] (methyl) azan
- α-methylfentanyl N-phenyl-N-[1-(1-phenyl-propane-2-yl)-4-piperidyl] propanamide
- 3-Methylfentanyl (mefentanyl) N-(3-Methyl-1-phenethyl-4-piperidyl) -N-phenylpropanamide
- Methylmethaqualone 3-(2,4-Dimethylphenyl)-2-methyl-quinazolin-4 (3H)-one
- 3-Methylmethcathinone
(3-MMC)
2-(methylamino) -1-(3-methylphenyl) propan-1-one
- 4-Methylmethcathinone
(Mephedron)
1-(4-Methylphenyl) -2-methylaminopropan-1-one
- Methylphenylpropionoxypiperidine (MPPP) (1-Methyl-4-phenyl-4-piperidyl) propionate
- Methyl-3-phenylpropylamine (1M-3PP) (methyl) (3-phenylpropyl) azan
- Methylphenyltetrahydropyridine (MPTP) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
- Methylpiperidylbenzilate (1-Methyl-3-piperidyl) benzilate
- 4-Methylthioamfetamine (4-MTA) 1-[4-(Methylsulfanyl) phenyl] propan-2-ylazane
- α-methylthiofentanyl N-phenyl-N-{1-[1-(2-thienyl)-propane-2-yl]-4-piperidyl} propanamide
- 3-Methylthiofentanyl N-{3-methyl-1-[2-(2-thienyl) ethyl]-4-piperidyl}-N-phenyl-propanamide
- α-methyltryptamine (α-MT) 1-(Indol-3-yl) propan-2-ylazane
Metopon 5-Methyldihydromorphinone 4,5α-epoxy-3-hydroxy-5, 17-dimethylmorphinan-6-one
Morpheridin - Ethyl (1-(2-morpholinoethyl) -4-phenylpiperidine-4-carboxylate)
- Morphine-N-oxide (5R, 6S) -4,5-epoxy-3,6-dihydroxy-17-methylmorphin-7-ene-17-oxide
Myrophin Myristylbenzylmorphine (3-Benzyloxy-4, 5α-epoxy-17-methylmorphin-7-en-6-yl) tetradecanoate
Nicomorphine 3.6-Dinicotinoylmorphine 4,5α-Epoxy-17-methyl-morphin-7-en-3,6α-diyl) dinicotinate
Noracymethadol - (6-Methylamino-4,4-diphenyl-heptane-3-yl) acetate
Norcodeine N-desmethylcodeine 4,5α-Epoxy-3-methoxy-morphin-7-en-6α-ol
Norlevorphanol (-) 3-Hydroxymorphinan (9R, 13R, 14R) -Morphinan-3-ol
Normorphine Desmethylmorphine 4,5α-epoxymorphine-7-ene-3,6α-diol
Norpipanon - 4,4-diphenyl-6-piperidinohexan-3-one
- Parahexyl 3-Hexyl-6,6,9-trimethyl-7,8,9, 10-tetrahydro-6H-benzo [c] chromen-1-ol
- PCPr (1-phenylcyclohexyl) (propyl) azan
- Pentylon
(bk-MBDP)
1-(1,3-Benzodioxol-5-yl) -2-(methylamino) pentan-1-one
Phenadoxon - 6-morpholino-4,4-diphenyl-heptane-3-one
Phenampromide - N-phenyl-N-(1-piperidinopropane-2-yl) propanamide
Phenazocin - 6,11-Dimethyl-3-phenethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
Phencyclidine PCP 1-(1-phenylcyclohexyl) piperidine
- Phenethylphenylacetoxypipederidine (PEPAP) (1-phenethyl-4-phenyl-4-piperidyl) acetate
- Phenethylphenyltetrahydropyridine (PEPTP) 1-phenethyl-4-phenyl-1,2,3,6-tetrahydropyridine
Phenpromethamine 1-Methylamino-2-phenyl-propane (PPMA) (methyl) (2-phenylpropyl) azan
Phenomorphan - 17-phenethylmorphinan-3-ol
Phenoperidine - Ethyl [1-(3-hydroxy-3-phenyl-propyl)-4-phenylpiperidine-4-carboxylate]
Piminodin - Ethyl [1-(3-anilinopropyl) -4-phenylpiperidine-4-carboxylate]
- PPP 1-phenyl-2-(pyrrolidin-1-yl) propan-1-one
Proheptazine - (1 ,3-dimethyl-4-phenylazepan-4-yl) propionate
Properidin - Isopropyl (1-methyl-4-phenyl-piperidin-4-carboxylate)
- Psilocin (Psilotsin) 3-(2-Dimethylaminoethyl) indol-4-ol
- Psilocin-(eth) 3-(2-diethylaminoethyl) indol-4-ol
Psilocybin - [3-(2-Dimethylaminoethyl) indol-4-yl] dihydrogen phosphate
- Psilocybin-(eth) [3-(2-diethylaminoethyl) indol-4-yl] dihydrogen phosphate
- - 2-(pyrrolidin-1-yl) -1-(p-tolyl) propan-1-one
Racemethorphan - (9RS, 13RS, 14RS) -3-methoxy-17-methylmorphinan
RoClip clidin PHP (PCPy) 1-(1-phenylcyclohexyl) pyrrolidine
- Salvia divinorum
(plants and plant parts)
-
Tenamfetamine Methylenedioxyamfetamine (MDA) (RS) -1-(1,3-Benzodioxol-5-yl) propan-2-ylazane
Tenocyclidine TCP 1-[1-(2-Thienyl) cyclohexyl] piperidine
Tetrahydrocannabinols, the following isomers and their stereochemical variants:
- Δ6a (10a) -tetrahydrocannabinol
(Δ6a (10a) -THC)
6,6,9-trimethyl-3-pentyl-7,8,9, 10-tetrahydro-6H-benzo [c] chromen-1-ol
- Δ6a-tetrahydrocannabinol
(Δ6a-THC)
(9R, 10aR)-6,6,9-Trimethyl-3-pentyl-8,9, 10, 10a-tetra-hydro-6H-benzo [c] chromene-1-ol (6aR, 9R, 10aR) -6,6,9-trimethyl-3-pentyl-6a, 9, 10, 10a-tetrahydro-6H-benzo [c] chromen-1-ol
- Δ7-tetrahydrocannabinol
(Δ7-THC)
- Δ8-tetrahydrocannabinol
(Δ8-THC)
(6aR, 10aR)-6,6,9-Trimethyl-3-pentyl-6a, 7, 10, 10a-tetra-hydro-6H-benzo [c] chromene-1-ol (6aR) -6,6,9-trimethyl-3-pentyl-6a, 7,8,9-tetrahydro-6H-benzo [c] chromen-1-ol
- Δ10 -tetrahydrocannabinol
(Δ10-THC)
- Δ9 (11) -tetrahydrocannabinol
(Δ9 (11) -THC)
(6aR, 10aR) -6,6-dimethyl-9-methylen-3-pentyl-6a, 7,8,9, 10, 10a-hexahydro-6H-benzo [c] chromen-1-ol
- Thenyl fentanyl N-phenyl-N-(1-thenyl-4-piperidyl) propanamide
- Thienoamfetamine
(Thiopropamine)
1-(Thiophen-2-yl) propane-2-amine
- Thiofentanyl N-phenyl-N-{1-[2-(2-thienyl) ethyl]-4-piperidyl} propanamide
Trimeperidine - (1 ,2,5-trimethyl-4-phenyl-4-piperidyl) propionate
- Trimethoxyamfetamine (TMA) 1-(3,4,5-Trimethoxyphenyl) propan-2-ylazane
- 2,4,5-Trimethoxyamfetamine (TMA-2) 1-(2,4,5-trimethoxyphenyl) propan-2-ylazane
-
the esters, ethers and molecular compounds of the substances listed in this Annex, if they are not listed in another plant, and the existence of such esters, ethers and molecular compounds is possible;
-
the salts of the substances listed in this Annex, if the existence of such salts is possible;
-
the preparations of the substances listed in this Annex if they are not
a)
not to be used on or in the human or animal body, solely for diagnostic or analytical purposes, and where the content of one or more stunning agents does not exceed 0.001 of the hundred or the substances in the preparations are isotopenmodified or
b)
are particularly excluded;
-
the stereoisomers of the substances listed in this or any other plant if they are to be used as a narcotic agent;
-
Substances as defined in Article 2 (1) (1) (b) to (d) with substances listed in this or any other plant, and the biological materials suitable for the reproduction or production of substances in accordance with Article 2 (1) (1) (b) to (d), if: an abuse is provided for noise purposes.
Unofficial table of contents

Annex II (to § 1 (1))
(marketable, but non-prescription narcotics)

(Fundstelle: BGBl. I 2001, 1187-1189;
with regard to of the individual amendments. Footnote)

Column 1 contains the International Nonproprietary Names (INN) of the World Health Organization. In the name of a substance, the INN takes precedence over all other names.
Column 2 contains other non-protected fabric names (abbreviated names or trivial names). If an INN does not exist for a substance, its unique label can be used to use the name in bold in this column. All other non-bold names are not scientifically clear. They must therefore be used in conjunction with the designation in column 3.
Column 3 contains the chemical substance name according to the nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no name is listed in column 1 or 2, then the column 3 is to be used.
INN other unprotected or trivial names chemical names (IUPAC)
- AB-CHMINACA N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(cyclohexylmethyl) -1H-indazol-3-
carboxamide
- AB-FUBINACA N-(1-amino-3-methyl-1-oxobutane-
2-yl) -1-[(4-fluorophenyl) methyl] -1-[(4-fluorophenyl) methyl] -1H-
indazole-3-carboxamide
- AB-PINACA N-(1-amino-3-methyl-1-oxobutane-
2-yl) -1-pentyl-1H-indazole-3-carboxamide
- 1-Adamantyl (1-pentyl-1H-indol-3-yl) methanone (Adamantan-1-yl) (1-pentyl-1H-indol-3-yl) methanone
- AH-7921
(Doxylam)
3,4-dichloro-N-{ [ 1-(dimethylamino)
cyclohexyl] methyl } benzamide
- AKB-48 (APINACA) N-(adamantan-1-yl) -1-pentyl-1H-indazole-3-carboxamide
- AKB-48F N-(adamantan-1-yl) -1-(5-fluoropentyl) -1H-indazole-3-carboxamide
- AM-694 [1-(5-Fluoropentyl) -1H-indol-3-yl] (2-iodophenyl) methanone
- AM-1220 {1-[(1-Methylpiperidin-2-yl) methyl] -1H-indol-3-yl} (naphthalen-1-yl) methanone
- AM-1220-Azepan [1-(1-Methylazepan-3-yl) -1H-indol-3-yl] (naphthalen-1-yl) methanone
- AM-2201 [1-(5-Fluoropentyl) -1H-indol-3-yl] (naphthalen-1-yl) methanone
- AM-2232 5-[3-(naphthalene-1-carbonyl) -1H-indol-1-yl] pentanenitrile
- AM-2233 (2-Iodphenyl) {1-[(1-methylpiperidin-2-yl) methyl] -1H-indol-3-yl} methanone
Amfetaminil - (phenyl) [(1-phenylpropan-2-yl) amino] acetonitrile
Amineptin - 7-(10, 11-dihydro-5H-dibenzo [a, d] [7] annulen-5-ylamino) heptanoic acid
Aminorex - 5-Phenyl-4,5-dihydro-1,3-oxazol-2-ylazane
- 5-APB 1-(benzofuran-5-yl) propane-2-amine
- 6-APB 1-(Benzofuran-6-yl) propane-2-amine
- APICA
(SDB-001, 2NE1)
N-(adamantan-1-yl) -1-pentyl-1H-
Indole-3-carboxamide
- BB-22
(QUCHIC)
Quinolin-8-yl [1-(cyclohexylmethyl) -1H-indole-3-carboxylate]
- Benzylpiperazine (BZP) 1-benzylpiperazine
- Buphedron 2-(methylamino) -1-phenylbutan-1-one
Butalbital - 5-Allyl-5-isobutylbarbituric acid
- Butobarbital 5-butyl-5-ethylpyrimidine-2,4,6 (1H, 3H, 5H)-trione
- Butylon 1-(Benzo [d] [1, 3] dioxol-5-yl) -2-
(methylamino) butan-1-on
- Cannabis
(marijuana, plants and plant parts of plants belonging to the genus Cannabis)
-
-provided that they are intended for the manufacture of preparations for medical purposes,
Cetobemidon Ketobemidon 1-[4-(3-Hydroxyphenyl) -1-methyl-4-piperidyl] propan-1-one
- meta-chlorophenylpiperazine (m-CPP) 1-(3-Chlorophenyl) piperazine
- d-Cocaine Methyl (3ß-(benzoyloxy) tropane-2alpha-carboxylate)
- CP 47,497 (cis-3-[4-(1,1-dimethylheptyl) -2-hydroxyphenyl] cyclohexanol) 5-(1,1-dimethylheptyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
- CP 47 ,497-C6-Homolog (cis-3-[4-(1,1-dimethylhexyl) -2-hydroxyphenyl] cyclohexanol) 5-(1,1-dimethylhexyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
- CP 47 ,497-C8-Homolog (cis-3-[4-(1,1-Dimethyloctyl) -2-hydroxyphenyl]-cyclohexanol) 5-(1,1-Dimethyloctyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
- CP 47 ,497-C9-Homolog (cis-3-[4-(1,1-dimethylnonyl) -2-hydroxyphenyl] cyclohexanol) 5-(1,1-dimethylnonyl) -2-[(1RS, 3SR) -3-hydroxycyclohexyl] phenol
Cyclobarbital - 5-(cyclohex-1-en-1-yl) -5-ethylpyrimidine-2,4,6 (1H, 3H, 5H)-trione
- Desoxypipradrol
(2-DPMP)
2-(diphenylmethyl) piperidine
- Dextromethadone (S) -6-dimethylamino-4,4-diphenylheptan-3-one
Dextromoramide - (S) -3-methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl) butan-1-one
Dextropropoxyphene - [(2S, 3R) -4-dimethylamino-3-methyl-1,2-diphenylbutan-2-yl] propionate
- Diamorphine [(5R, 6S) -4,5-epoxy-17-methylmorphine-7-ene-3,6-diyl] diacetate
-
provided that it is intended for the manufacture of preparations for medical purposes,
Difenoxin - 1-(3-Cyan-3,3-diphenylpropyl) -4-phenylpiperidine-4-carboxylic acid
-
with the exception of preparations containing up to 0.5 mg of difenoxine, calculated as the base and, in relation to this quantity, of at least 5 of the hundred atropine sulphate, without any other substance in Annexes I to III,
- Dihydromorphine 4,5α-epoxy-17-methylmorphinan-3,6α-diol
- Dihydrothebain 4,5α-epoxy-3,6-dimethoxy-17-methylmorphine-6-ene
- Dimethocaine
(DMC, Larocain)
(3-diethylamino-2,2-dimethylpropyl) -4-aminobenzoate
- 2,5-Dimethoxy-4-iodamfetamine
(DOI)
1-(4-iodo-2,5-dimethoxyphenyl) propane-2-amine
- 3,4-Dimethylmethcathinone (3 ,4-DMMC) 1-(3,4-Dimethylphenyl) -2-(methylamino) propan-1-one
Diphenoxylate - Ethyl [1-(3-cyano-3,3-diphenylpropyl) -4-phenylpiperidine-4-carboxylate]
-
with the exception of preparations containing up to 0.25 mg of diphenoxylate, calculated as base, and, based on these quantities, of at least 1 of the hundred atropine sulphate, without any other substance in Annexes I to III, up to a maximum of 0.25 mg of diphenoxylate or per divided form, included-
- 4,4 ' -DMAR
(para-methyl-4-methylaminorex)
4-Methyl-5-(4-methylphenyl) -4,5-
dihydro-1,3-oxazol-2-amine
- EAM-2201
(5-fluoro-JWH-210)
(4-ethylnaphthalen-1-yl) [1-(5-fluoropentyl) -1H-indol-3-yl] methanone
- Ecgonin 3β-hydroxytropane-2β-carboxylic acid
- Erythroxylum coca
(Plants and plant parts of the plants belonging to the species Erythroxylum coca-including the varieties bolivianum, spruceanum and novogranatense-belonging to the species)
-
- Ethcathinon (RS) -2-(Ethylamino) -1-
Phenylpropan-1-one
Ethchlorvynol - 1-chloro-3-ethylpent-1-en-4-in-3-ol
Ethinamate - (1-ethynylcyclohexyl) carbamate
- 3-O-ethylmorphine
(ethylmorphine)
4,5α-epoxy-3-ethoxy-17-methylmorphin-7-en-6α-ol
-
with the exception of preparations containing up to 100 mg of ethylmorphine, calculated as the base, without any other substance in Annexes I to III, up to 2.5 from 100 or in each form,
- Ethyl phenidate Ethyl [2-(phenyl) -2-(piperidin-2-yl) acetate]
Etilamfetamine N-ethylamphetamine (ethyl) (1-phenylpropan-2-yl) azan
- 5F-ABICA
(5F-AMBICA, 5-fluoro-ABICA, 5-fluoro-AMBICA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(5-fluoropentyl) -1H-indole-3-carboxamide
- 5F-AB-PINACA
(5-fluoro-AB-PINACA)
N-(1-amino-3-methyl-1-oxobutan-2-yl)-
1-(5-fluoropentyl) -1H-indazol-3-
carboxamide
- 5F-AMB
(5-Fluoro-AMB)
Methyl { 2- [ 1- (5-fluoropentyl) -1H-indazole-
3-carboxamido] -3-methylbutanoate }
- FDU-PB-22 Naphthalen-1-yl {1 [(4-fluorophenyl) methyl] -1H-indole-3-carboxylate}
Fencamfamine - N-ethyl-3-phenylbicyclo [2.2.1] heptane-2-amine
- Flephedron (4-Fluoromethcathinon, 4-FMC) 1-(4-Fluorophenyl) -2-(methylamino) propan-1-one
- 4-Fluoromethamfetamine (4-FMA) 1-(4-Fluorophenyl) -N-methylpropan-2-amine
- 3-Fluoromethcathinone (3-FMC) 1-(3-Fluorophenyl) -2-(methylamino) propan-1-one
- 5-Fluoropentyl-JWH-122 (MAM-2201) [1-(5-Fluoropentyl) -1H-indol-3-yl] (4-methylnaphthalen-1-yl) methanone
- p-fluorophenylpiperazine (p-FPP) 1-(4-Fluorophenyl) piperazine
- 4-Fluortropacocaine 3-(4-fluorobenzoyloxy) tropic
- 5-fluoro-UR-144 (XLR-11) [1-(5-Fluoropentyl) -1H-indol-3-yl] (2 ,2,3,3-tetramethylcyclopropyl) methanone
- 5F-PB-22
(5F-QUPIC)
Quinolin-8-yl [1-(5-fluoropentyl) indole-3-carboxylate]
- 5F-SDB-006 N-Benzyl-1-(5-fluoropentyl) -1H
-indole-3-carboxamide
- FUB-PB-22 Quinolin-8-yl {1-[(4-fluorophenyl) methyl] -1H-indole-3-carboxylate}
Glutethimide - 3-ethyl-3-phenylpiperidine-2,6-dione
- Isocodeine 4,5α-epoxy-3-methoxy-17-methylmorphin-7-en-6ß-ol
Isomethadone - 6-Dimethylamino-5-methyl-4,4-diphenylhexan-3-one
- JWH-007 (2-methyl-1-pentyl-1H-indol-3-yl) (naphthalen-1-yl) methanone
- JWH-015 (2-methyl-1-propyl-1H-indol-3-yl) (naphthalen-1-yl) methanone
- JWH-018
(1-pentyl-3-(1-naphthoyl) indole)
(naphthalen-1-yl) (1-pentyl-1H-indol-3-yl) methanone
- JWH-019
(1-Hexyl-3-(1-naphthoyl) indole)
(naphthalen-1-yl) (1-hexyl-1H-indol-3-yl) methanone
- JWH-073
(1-butyl-3-(1-naphthoyl) indole)
(naphthalen-1-yl) (1-butyl-1H-indol-3-yl) methanone
- JWH-081 (4-methoxynaphthalen-1-yl) (1-
pentyl-1H-indol-3-yl) methanone
- JWH-122 (4-Methylnaphthalen-1-yl) (1-pentyl-1H-indol-3-yl) methanone
- JWH-200 [1-(2-morpholinoethyl) -1H-indol-3-yl] (naphthalen-1-yl) methanone
- JWH-203 2-(2-chlorophenyl) -1-(1-pentyl-1H-indol-3-yl) ethanone
- JWH-210 (4-ethylnaphthalen-1-yl) (1-pentyl-1H-indol-3-yl) methanone
- JWH-250
(1-Pentyl-3-(2-methoxy-phenylacetyl) indole)
2-(2-Methoxyphenyl) -1-(1-pentyl-1H-indol-3-yl) ethanone
- JWH-251 2-(2-methylphenyl) -1-(1-pentyl-1H-indol-3-yl) ethanone
- JWH-307 [5-(2-Fluorophenyl) -1-pentyl-1H-pyrrol-3-yl] (naphthalen-1-yl) methanone
Levamfetamine Levamphetamine (R) -1-phenylpropan-2-ylazane
- Levmetamfetamine (levometamfetamine) (R)-(methyl) (1-phenylpropan-2-yl) azan
Levomoramide - (R) -3-methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl) butan-1-one
Levorphanol - (9R, 13R, 14R) -17-methylmorphinan-3-ol
Mazindol - 5-(4-chlorophenyl) -2,5-dihydro-3H-imidazole [2,1-a] isoindol-5-ol
Mefenorex - 3-chloro-N-(1-phenylpropane-2-yl)-propane-1-amine
Meprobamate - (2-methyl-2-propylpropane-1,3-diyl) dicarbamate
Mesocarb - (phenylcarbamoyl) [3-(1-phenylpropan-2-yl) -1,2,3-oxadiazol-3-ium-5-yl] azanide
Metamfetamine Methamphetamine (2S)-N-methyl-1-phenylpropan-2-amine
(RS) -Metamfetamine Metamfetamine racemate (RS)-(methyl) (1-phenylpropan-2-yl) azan
- Methadone intermediate (premethadone) 4-dimethylamino-2,2-diphenylpentannitrile
Methaqualon - 2-methyl-3-(2-methylphenyl) quinazolin-4 (3H)-one
- Methedrone (4-methoxymethcathinone, PMMC) 1-(4-Methoxyphenyl) -2-(methylamino) propan-1-one
- p-methoxyethylamfetamine (PMEA) N-ethyl-1-(4-methoxyphenyl) propan-2-amine
- 4-Methylamfetamine 1-(4-Methylphenyl) propane-2-amine
- Methylbenzylpiperazine (MBZP) 1-benzyl-4-methylpiperazine
- 3,4-Methylenedioxypyrovalerone (MDPV) 1-(Benzo [d] [1, 3] dioxol-5-yl) -2-(pyrrolidin-1-yl) pentan-1-one
- 4-Methylethcathinon (4-MEC) 2-(Ethylamino) -1-(4-methylphenyl) propan-1-one
- Methylon (3 ,4-Methylenedioxy-N-methcathinone, MDMC) 1-(Benzo [d] [1, 3] dioxol-5-yl) -2-(methylamino) propan-1-one
(RS; SR)-methylphenidate - Methyl [(RS; SR) (phenyl) (2-piperidyl) acetate]
Methyprylon - 3,3-diethyl-5-methylpiperidine-2,4-dione
- Poppy straw concentrate
(the material obtained in the processing of plants and parts of the plant of the species Papaver somniferum for the concentration of the alkaloids)
-
- Moramide intermediate (Premoramide) 3-Methyl-4-morpholino-2,2-diphenylbutanoic acid
- MT-45 1-cyclohexyl-4-(1,2-diphenylethyl)
piperazine
- Naphyron (naphthylpyrovalerone) 1-(naphthalen-2-yl) -2-(pyrrolidin-1-yl) pentan-1-one
Nicocodin 6-Nicotinoylcodeine (4 ,5α-epoxy-3-methoxy-17-methylmorphin-7-en-6α-yl) nicotinate
Nicodicodin 6-Nicotinoyldihydrocodeine (4 ,5α-epoxy-3-methoxy-17-methylmorphinan-6α-yl) nicotinate
- Oripavin 4,5α-epoxy-6-methoxy-17-methylmorphina-6,8-dien-3-ol
Oxymorphon 14 -Hydroxydihydromorphinone 4,5α-epoxy-3, 14-dihydroxy-17-methylmorphinan-6-one
- Papaver bracteatum
(plants and parts of plants, other than the seeds, plants belonging to the species Papaver bracteatum)
-
-
except for ornamentals,
- PB-22
(QUPIC)
Quinolin-8-yl (1-pentylindol-3-carboxylate)
- Pentedron 2-(methylamino) -1-phenylpentan-1-one
- Pethidine intermediate A (prepethidine) 1-Methyl-4-phenylpiperidine-4-carbonitrile
- Pethidine intermediate B (norpethidine) Ethyl (4-phenylpiperidine-4-carboxylate)
- Pethidine intermediate C (Pethidinic acid) 1-Methyl-4-phenylpiperidine-4-carboxylic acid
Phendimetrazine - (2S, 3S) -3,4-dimethyl-2-phenylmorpholine
Phenmetrazine - 3-Methyl-2-phenylmorpholine
Pholcodin Morpholinylethylmorphine 4,5α-epoxy-17-methyl-3-(2-morpholinoethoxy) morphin-7-en-6α-ol
-
except in preparations which contain, without a further substance from Annexes I to III, as a solution up to 0.15 per cent, but not more than 150 mg per pack unit, or up to 20 mg per unit of Pholcodin, calculated as base,
Propiram - N-(1-piperidinopropan-2-yl) -N-(2-pyridyl) propanamide
Pyrovaleron - 2-(pyrrolidin-1-yl) -1-(ρ-tolyl) pentan-1-one
- α-pyrrolidine ovalerophenone (α-PVP) 1-phenyl-2-(pyrrolidin-1-yl) pentan-1-one
Racemoramid - (RS) -3-methyl-4-morpholino-2,2-diphenyl-1-(pyrrolidin-1-yl) butan-1-one
Racemorphan - (9RS, 13RS, 14RS) -17-methylmorphinan-3-ol
- RCS-4 (4-Methoxyphenyl) (1-pentyl-1H-indol-3-yl) methanone
- RCS-4 ortho isomer (o-RCS-4) (2-Methoxyphenyl) (1-pentyl-1H-indol-3-yl) methanone
- SDB-006 N-Benzyl-1-pentyl-1H-indol-3-
carboxamide
Secbutabarbital Butabarbital 5-(Butan-2-yl) -5-ethylpyrimidine-2,4,6 (1H, 3H, 5H)-trione
- STS-135
(5F-2NE1)
N-(adamantan-1-yl) -1-(5-fluoropentyl) -1H-indole-3-carboxamide
- Δ9-tetrahydrocannabinol
(Δ9-THC)
6,6,9-trimethyl-3-pentyl-6a, 7,8, 10a-tetrahydro-6H-benzo [c] chromen-1-ol
- Tetrahydrothebain 4,5α-epoxy-3,6-dimethoxy-17-methylmorphinan
Thebacon Acetyldihydrocodeinon (4 ,5α-epoxy-3-methoxy-17-methylmorphine-6-en-6-yl) acetate
- Thebain 4,5α-epoxy-3,6-dimethoxy-17-methylmorphina-6,8-diene
- THJ-018
(JWH-018 Indazol-analogue)
(naphthalen-1-yl) (1-pentyl-1H-indazole-
3-yl) methanone
- THJ-2201
(AM-2201 Indazol-analogue)
[1-(5-Fluoropentyl) -1H-indazol-3-yl] (naphthalen-1-yl) methanone
cis-Tilidin - Ethyl [(1RS, 2RS) -2-dimethylamino-1-phenylcyclohex-3-enecarboxylate]
- 3-trifluoromethylphenylpiperazine (TFMPP) 1-[3-(trifluoromethyl) phenyl] piperazine
- UR-144 (1-pentyl-1H-indol-3-yl) (2,2,3,3-tetramethylcyclopropyl) methanone
Vinyl bital - 5-Ethenyl-5-(pentan-2-yl) pyrimidine-2,4,6 (1H, 3H, 5H)-trione
Zipeprol - 1-methoxy-3-[4-(2-methoxy-2-phenylethyl) piperazin-1-yl] -1-phenylpropan-2-ol
-
the esters, ethers and molecular compounds of the substances listed in this Appendix and the esters and ethers of the substances listed in Annex III, excluding gamma-hydroxybutyric acid (GHB), if they are not listed in another plant and the existence of such compounds; Esters, ethers and molecular compounds are possible;
-
the salts of the substances listed in this Annex, if the existence of such salts is possible, and the salts and molecular compounds of the substances listed in Annex III, if the existence of such salts and molecular compounds is possible and if they are: are not used in medical, dental or veterinary medicine;
-
the preparations of the substances listed in this Annex if they are not
a)
without being used on or in the human or animal body, solely for diagnostic or analytical purposes and containing one or more narcotic agents, lyophilisates and accordingly to be used Mixtures of substances in the ready-to-use solution, in each case not exceeding 0.01 of the hundred, or the substances in the preparations isotopenmodified or
b)
are particularly excluded.
Unofficial table of contents

Annex III (to § 1 (1))
Marketable and marketable narcotics

(Fundstelle: BGBl. I 2001, 1189-1195;
with regard to of the individual amendments. Footnote)
Column 1 contains the International Nonproprietary Names (INN) of the World Health Organization. In the name of a substance, the INN takes precedence over all other names.
Column 2 contains other non-protected fabric names (abbreviated names or trivial names). If an INN does not exist for a substance, its unique label can be used to use the name in bold in this column. All other non-bold names are not scientifically clear. They must therefore be used in conjunction with the designation in column 3.
Column 3 contains the chemical substance name according to the nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If no name is listed in column 1 or 2, then the column 3 is to be used.
INN other unprotected or trivial names chemical names (IUPAC)
Alfentanil - N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl) ethyl] -4-methoxymethyl-4-piperidyl} -N-phenylpropanamide
Allorbarbital - 5,5-Diallylbarbituric acid
Alprazolam - 8-Chloro-1-methyl-6-phenyl-4H-[1,2, 4] triazolo [4,3-a] [1, 4] benzodiazepine
-
with the exception of preparations containing up to 1 mg of alprazolam in the absence of any other substance in Annexes I to III,
Amfepramon Diethylpropion 2-diethylamino-1-phenylpropan-1-one
-
with the exception of preparations without delayed release of active substances, which, without any other substance in Annexes I to III, are up to 22 mg each, and in preparations with delayed release of active substances, without any other substance in Annexes I to III. III per divided form, up to 64 mg of amfepramon, calculated as base,
Amfetamine Amphetamine (RS) -1-phenylpropan-2-ylazane
Amobarbital - 5-ethyl-5-isopentylbarbituric acid
Barbital - 5,5-diethylbarbituric acid
-
except in preparations which:
a)
without a further substance in Annexes I to III up to 10 per hundred or
b)
without being used on or in the human or animal body, solely for diagnostic or analytical purposes, and without any further substance in Annexes I to III, not more than 25 g of Barbital, calculated as a acid, contain-
Bromazepam - 7-bromo-5-(2-pyridyl) -1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 6 mg of bromazepam without any other substance in Annexes I to III,
Brotizolam - 2-Bromo-4-(2-chlorophenyl) -9-methyl-6H-thieno [3,2-f] [1,2, 4] triazolo [4,3-a] [1, 4] diazepine
-
with the exception of preparations containing up to 0.02% or 0.25 mg of brotizolam without any other substance in Annexes I to III, up to 0.02 per cent or in each divided form,
Buprenorphine - (5R, 6R, 7R, 14S)-17-Cyclopropyl-methyl-4,5-epoxy-7-[(S)-2-hydroxy-3,3-dimethylbutan-2-yl]-6-methoxy-6, 14-ethanomorphinan-3-ol
Camazepam - (7-Chloro-1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-enzodiazepin-3-yl) (dimethylcarbamate)
- Cannabis
(marijuana, plants and plant parts of the genus cannabis
Plants)
-
-only in preparations which are authorised as ready-to-use medicinal products,
Cathin (+)-Norpseudoephedrine (D-Norpseudoephedrine) (1S, 2S) -2-amino-1-phenylpropan-1-ol
-
with the exception of preparations containing up to 5 of the 100 mg as a solution but not more than 1 600 mg per unit of package or per unit of form up to 40 mg of cathin, calculated as the base, without any other substance in Annexes I to III,
Chlordiazepoxide - 7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide
-
with the exception of preparations containing up to 25 mg of chlordiazepoxide oxide without any other substance in Annexes I to III,
Clobazam - 7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,5-benzodiazepin-2,4 (5H)-dione
-
with the exception of preparations containing up to 30 mg of clobazam in the absence of any other substance in Annexes I to III,
Clonazepam - 5-(2-chlorophenyl) -7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
-
with the exception of preparations containing up to 0.25 of the hundred as a drip solution, but not more than 250 mg per pack unit or per form divided up to 2 mg of clonazepam, without any other substance in Annexes I to III,
Clorazepate - (RS) -7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid
-
with the exception of preparations containing up to 50 mg, as dry matter only for parenteral use, of up to 100 mg, of clorazepate as a dipotassium salt, without any other substance in Annexes I to III, as dry matter.
Clotiazepam - 5-(2-chlorophenyl) -7-ethyl-1-methyl-1,3-dihydro-2H-thieno [2,3-e] [1, 4] diazepin-2-one
-
with the exception of preparations containing up to 20 mg of clotiazepam in the absence of any other substance in Annexes I to III,
Cloxazolam - 10-Chloro-11b-(2-chlorophenyl) -2,3,7, 11b-tetrahydro [1, 3] oxazolo [3,2-d] [1, 4] benzodiazepin-6 (5H)-one
- Cocaine (benzoylecgonine methyl ester) Methyl [3ß-(benzoyloxy) tropane-2β-carboxylate]
- Codeine (3-Methylmorphine) 4,5α-epoxy-3-methoxy-17-methylmorphin-7-en-6α-ol
-
with the exception of preparations containing up to 100 mg of codeine, calculated as base, without any other substance in Annexes I to III, up to 2.5 of the hundred or per divided form. However, the provisions relating to the prescribing and the release of narcotic drugs shall apply to excluded preparations which are prescribed for persons dependent on stunnents or alcohol.
Delorazepam - 7-Chloro-5-(2-chlorophenyl) -1,3-dihydro-2H-1,4-benzodiazepine-2-one
Dexamfetamine Dexamphetamine (S) -1-phenylpropan-2-ylazane
Dexmethylphenidate - Methyl [(R, R) (phenyl) (2-piperidyl) acetate]
- Diamorphine [(5R, 6S) -4,5-epoxy-17-methylmorphine-7-ene-3,6-diyl] diacetate
-
only in preparations which are authorised for substitution treatment,
Diazepam - 7-Chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 1 in 100 mg of syrup or drip solution, but not more than 250 mg per pack unit, or up to 10 mg of diazepam, without any other substance in Annexes I to III,
Dihydrocodeine - 4,5α-epoxy-3-methoxy-17-methylmorphinan-6α-ol
-
with the exception of preparations containing up to 100 mg of dihydrocodeine, calculated as the base, without any other substance in Annexes I to III, up to 2.5 of the hundred or in each divided form. However, the provisions relating to the prescribing and the release of narcotic drugs shall apply to excluded preparations which are prescribed for persons dependent on stunnents or alcohol.
Dronabinol - (6aR, 10aR) -6,6,9-trimethyl-3-pentyl-6a, 7,8, 10a-tetrahydro-6H-benzo [c] chromen-1-ol
Estazolam - 8-chloro-6-phenyl-4H-[1,2, 4] triazolo [4,3-a] benzodiazepine
-
with the exception of preparations containing up to 2 mg of estazolam in the absence of any other substance in Annexes I to III,
Ethylloflaepate - Ethyl [7-chloro-5-(2-fluorophenyl) -2-oxo-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylate]
Etizolam - 4-(2-chlorophenyl) -2-ethyl-9-methyl-6H-thieno [3,2-f] [1,2, 4] triazolo [4,3-a] [1, 4] diazepine
Etorphine - (5R, 6R, 7R, 14R) -4,5-epoxy-7-[(R) -2-hydroxypentan-2-yl] -6-methoxy-17-methyl-6, 14-ethenomorphinan-3-ol
Fenetyllin - 1,3-dimethyl-7-[2-(1-phenylpropan-2-ylamino) ethyl] -3,7-dihydro-2H-purin-2,6 (1H)-dione
Fenproporex - (RS) -3-(1-phenylpropan-2-ylamino) propannitrile
-
with the exception of preparations containing up to 11 mg of fenproporex, calculated as base, without any other substance in Annexes I to III,
Fentanyl - N-(1-phenethyl-4-piperidyl) -N-phenylpropanamide
Fludiazepam - 7-Chloro-5-(2-fluorophenyl) -1-methyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
Flunitrazepam - 5-(2-Fluorophenyl) -1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Flurazepam - 7-Chloro-1-(2-diethylaminoethyl) -5-(2-fluorophenyl) -1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 30 mg of flurazepam in the absence of any other substance in Annexes I to III,
Halazepam - 7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl) -1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 120 mg of halazepam in the absence of any other substance in Annexes I to III,
Haloxazolam - 10-Brom-11b-(2-fluorophenyl) -2,3,7, 11b-tetrahydro [1, 3] oxazolo [3,2-d] [1, 4] benzodiazepin-6 (5H)-one
Hydrocodon Dihydrocodeinon 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one
Hydromorphon Dihydromorphinon 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one
- γ-hydroxybutyric acid (GHB) 4-hydroxybutanoic acid
-
with the exception of preparations for injection, which contain up to 20% of gamma-hydroxybutyric acid, calculated as acid, without any other substance in Annexes I to III, up to 20 per cent and per divided form,
Ketazolam - 11-Chloro-2,8-dimethyl-12b-phenyl-8, 12b-dihydro-4H-[1, 3] oxazino [(3,2-d] [1, 4] benzodiazepine-4,7 (6H)-dione
-
with the exception of preparations containing up to 45 mg of ketazolam in the absence of any other substance in Annexes I to III,
Levacetylmethadol Levomethadyl acetate (LAAM) [(3S, 6S) -6-dimethylamino-4,4-diphenylheptan-3-yl] acetate
Levomethadon - (R) -6-dimethylamino-4,4-diphenylheptan-3-one
Lisdexamfetamine - (2S)-2,6-Diamino-N-[(2S)-1-phenylpropane-2-yl] hexanamide
Loprazolam - 6-(2-chlorophenyl) -2-[(Z) -4-methylpiperazin-1-ylmethylene] -8-nitro-2,4-dihydro-1H-imidazo [1,2-a] [1, 4] benzodiazepine-1-one
-
with the exception of preparations containing up to 2.5 mg of Loprazolam without any other substance in Annexes I to III,
Lorazepam - (RS) -7-Chloro-5-(2-chlorophenyl) -3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 2.5 mg of lorazepam, without any other substance in Annexes I to III,
Lormetazepam - 7-Chloro-5-(2-chlorophenyl) -3-hydroxy-1-methyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 2 mg of lormetazepam in the absence of any other substance in Annexes I to III,
Medazepam - 7-Chloro-1-methyl-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine
-
with the exception of preparations containing up to 10 mg of meatam in the absence of any other substance in Annexes I to III,
Methadone - (RS) -6-dimethylamino-4,4-diphenylheptan-3-one
Methylphenidate - Methyl [(RS; RS) (phenyl) (2-piperidyl) acetate]
Methylphenobarbital Mephobarbital (RS)-5-ethyl-1-methyl-5-phenyl-barbituric acid
-
with the exception of preparations containing up to 200 mg of methylphenobarbital, calculated as the acid, without any other substance in Annexes I to III,
Midazolam - 8-Chloro-6-(2-fluorophenyl) -1-methyl-4H-imidazo [1,5-a] [1, 4] benzodiazepine
-
with the exception of preparations containing up to 15 mg of midazolam without any other substance in Annexes I to III, up to a maximum of 0.2 per cent or per divided form,
- Morphine (5R, 6S)-4,5-Epoxy-17-methyl-morphin-7-en-3,6-diol
Nabilon - (6aRS, 10aRS) -1-Hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl) -6, 6a, 7,8, 10, 10a-hexahydro-9H-benzo [c] chromen-9-one
Nimetazepam - 1-Methyl-7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
Nitrazepam - 7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 0.5 of the hundred as a drip solution, but not more than 250 mg per pack unit, or up to 10 mg of nitrazepam, in each form divided without a further substance in Annexes I to III,
Northazepam - 7-chloro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 0.5 of the hundred as a drip solution, but not more than 150 mg per unit of pack, or up to 15 mg of Nordazepam, per unit of packaging, without any other substance in Annexes I to III,
Normethadone - 6-Dimethylamino-4,4-diphenyl-hexan-3-one
- Opium
(the tanned juice of the plants belonging to the species Papaver somniferum)
-
-
except in preparations which are produced according to a process technique described in the homeopathic part of the medicinal product, if the final concentration does not exceed the sixth decimal potency,
Oxazepam - 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 50 mg of oxazepam without any other substance in Annexes I to III,
Oxazolam - (2RS, 11bSR) -10-chloro-2-methyl-11b-phenyl-2,3,7, 11b-tetrahydro [1, 3] oxazolo [3,2-d] [1, 4] benzodiazepin-6 (5H)-one
-
with the exception of preparations containing up to 20 mg of oxazolam in each form without a further substance in Annexes I to III,
Oxycodone 14 -Hydroxydihydrocodeinone 4,5α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
- Papaver somniferum
(plants and parts of plants, other than the seeds, plants belonging to the species Papaver somniferum (including the subspecies of setigum))
-
-
, except where the traffic is intended for ornamentals (except for the cultivation) and if, in the dried state, their content of morphine does not exceed 0.02 of the hundred; in this case, the anesthetic provisions shall apply to the application of on imports, exports and transit
-
except in preparations which are produced according to a process technique described in the homeopathic part of the medicinal product, if the final concentration does not exceed the fourth decimal potency,
-
with the exception of preparations containing up to 0.015 of the Hundred Morphine, calculated as the base, without a further substance from Annexes I to III, and which are composed of one or more other ingredients in such a way that the Anaesthetic cannot be recovered by means of easily applicable procedures or in an extent which is dangerous to public health,
Pemolin - 2-Imino-5-phenyl-1,3-oxazolidin-4-one
-
with the exception of preparations containing up to 20 mg of pemolin, calculated as the base, without any other substance in Annexes I to III,
Pentazocin - (2R, 6R, 11R) -6, 11-Dimethyl-3-(3-methylbut-2-en-1-yl) -1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol
Pentobarbital - (RS) -5-ethyl-5-(pentan-2-yl) barbituric acid
Pethidin - Ethyl (1-methyl-4-phenyl-piperidine-4-carboxylate)
- Phenazepam 7-Bromo-5-(2-chlorophenyl) -1,3-dihydro-2H-1,4-benzodiazepin-2-one
Phenobarbital - 5-ethyl-5-phenylbarbituric acid
-
with the exception of preparations containing up to 300 mg of phenobarbital, calculated as the acid, without any other substance in Annexes I to III, up to 10 per cent or in each divided form,
PhenDate - 2-benzylpropan-2-ylazane
-
with the exception of preparations containing up to 15 mg of Phentermin, calculated as the base, without any other substance in Annexes I to III,
Pinazepam - 7-chloro-5-phenyl-1-(prop-2-in1-yl) -1,3-dihydro-2H-1,4-benzodiazepine-2-one
Pipradrol - Diphenyl (2-piperidyl) methanol
Piritramid - 1 '-(3-Cyan-3,3-diphenylpropyl) [1,4'-bipiperidine] -4 '-carboxamide
Prazepam - 7-Chloro-1-cyclopropylmethyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 20 mg of Prazepam without any other substance in Annexes I to III,
Remifentanil - Methyl {3-[4-methoxycarbonyl-4-(N-phenylpropanamido) piperidino] propanoate}
Secobarbital - 5-Allyl-5-(pentan-2-yl) barbituric acid
Sufentanil - N-{4-methoxymethyl-1-[2-(2-thienyl) ethyl] -4-piperidyl} -N-phenylpropanamide
Tapentadol - 3-[(2R, 3R) -1-dimethylamino-2-methylpentan-3-yl] phenol
Temazepam - (RS) -7-chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 20 mg of temazepam without any other substance in Annexes I to III,
Tetrazepam - 7-chloro-5-(cyclohex-1-enyl) -1-methyl-1,3-dihydro-2H-1,4-benzodiazepine-2-one
-
with the exception of preparations containing up to 100 mg of tetrazepam in the absence of a further substance in Annexes I to III,
Tilidine trans-Tilidin Ethyl [(1RS, 2SR)-2-dimethyl-amino-1-phenylcyclohex-3-enecarboxylate]
-
, except in solid preparations with delayed release of active substances, which, without any other substance in Annexes I to III, per form divided up to 300 mg of Tilidin, calculated as base, and, in relation to this quantity, at least 7.5 from the hundred Naloxone hydrochloride contains-
Triazolam - 8-Chloro-6-(2-chlorophenyl) -1-methyl-4H-[1,2, 4] triazolo [4,3-a] [1, 4] benzodiazepine
-
with the exception of preparations containing up to 025 mg of triazolam without any other substance in Annexes I to III,
Zolpidem - N, N-Dimethyl-2-[ 6-methyl-2-(p-toly) imidazo [1,2-a] pyridin-3-yl] acetamide.
-
except in preparations for oral use, containing up to 8.5 mg of zolpidem, calculated as the base, without any other substance in Annexes I to III,
-
the salts and molecular compounds of the substances listed in this Annex, if they are applied in medical, dental or veterinary use, in accordance with the findings of medical science;
-
the preparations of the substances listed in this Annex if they are not
a)
not to be used on or in the human or animal body, to be used solely for diagnostic purposes and to be used in one or more narcotics, in the case of lyophilisates and accordingly to be used Mixtures of substances in the ready-to-use solution, in each case not exceeding 0.01 of the hundred, or the substances in the preparations isotopenmodified or
b)
are particularly excluded. However, the rules on the import, export and transit of drugs, other than those with codeine or dihydrocodeine, are subject to the rules governing the use of drugs. However, preparations which have been excluded under point (b) of the Barbital position may be used, withdrawn or carried out without authorisation in accordance with Article 11 of the Narcotics Act, if, in the circumstances, there is no reason to fear that the use of the preparations is unfair.